EP1856072A1 - Thiazole derivatives as ppar delta ligands and their manufacturing process - Google Patents

Thiazole derivatives as ppar delta ligands and their manufacturing process

Info

Publication number
EP1856072A1
EP1856072A1 EP06716113A EP06716113A EP1856072A1 EP 1856072 A1 EP1856072 A1 EP 1856072A1 EP 06716113 A EP06716113 A EP 06716113A EP 06716113 A EP06716113 A EP 06716113A EP 1856072 A1 EP1856072 A1 EP 1856072A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
group
atom
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06716113A
Other languages
German (de)
French (fr)
Other versions
EP1856072A4 (en
Inventor
Jungyeob 123-404 Gwanak dream town HAM
Hoosang 202-ho Ilheung villa HWANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seoul National University Industry Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from KR1020060018360A external-priority patent/KR100797798B1/en
Publication of EP1856072A1 publication Critical patent/EP1856072A1/en
Publication of EP1856072A4 publication Critical patent/EP1856072A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel thiazole derivatives represented by Formula I, as peroxisome proliferator-activated receptor ⁇ (PPAR ⁇ ) -activating ligands, which can be used for the treatment of obesity, hyperlipidemia, arteriosclerosis and diabetes, as well as their intermediates and preparation methods thereof:
  • PPAR ⁇ peroxisome proliferator-activated receptor ⁇
  • A is hydrogen, R 2 or " ORe
  • a peroxisome proliferator- activated receptor includes three subtypes: PPAR ⁇ , PPAR ⁇ , PPAR ⁇ ⁇ Nature, 1990, 347, p645-650., Proc. Natl. Acad. Sci. USA 1994, 91, p7335-7359).
  • PPAR ⁇ , PPAR ⁇ and PPAR ⁇ have functions distinguished according to in vivo tissues and are expressed in different sites.
  • PPAR ⁇ is expressed mainly in the human heart, kidneys, skeletal muscle and colon ⁇ Mol. Pharmacol. 1998, 53, pl4-22., Toxicol. Lett. 1999, 110, pll9- 127., J. Biol. Chem.
  • PPAR ⁇ is known to be expressed weakly in a skeletal muscle, but expressed largely in fat tissue, and thus involved in the differentiation of fat cells, the storage of energy in the form of fat, and the regulation of homeostasis of insulin and sugar ⁇ Moll. Cell. 1999, 4, p585-594., p597-609., p ⁇ ll-617).
  • PPAR ⁇ has been evolutionally conserved in Vertebrata, such as mammals, including human beings, rodents and Ascidiacea. Those found so far have been known as PPAR ⁇ in Xenopus laevis ⁇ Cell 1992, 68, p879-887), and as NUCI ⁇ Mol. Endocrinol. 1992, 6, pl634 ⁇ 1641), PPAR ⁇ (Proc. Natl. Acad. Sci. USA 1994, 91, p7355- 7359), NUCI ⁇ Biochem. Biophys . Res. Commun. 1993, 196, p671- 677), FAAR (J. Bio. Chem.
  • PPAR ⁇ is known to be present in chromosome 6 ⁇ 21. l-p21.2, whereas, in rats, the mRNA of PPAR ⁇ is found in the cells of various sites, but the amount thereof is shown to be lower than that of PPARcx and PPAR ⁇ ⁇ Endocrinology 1996, 137, p354-366., J. Bio. Chem. 1995, 270, p2367-2371., Endocrinology 1996, 131, p354-366) .
  • PPAR ⁇ is known to play an important in an expression process ⁇ Genes Dev. 1999, 13, pl561-1574. ) , and to perform physiological functions, including the differentiation of nervous cells in the central nervous system (CNS) (J. Chem. Neuroanat 2000, 19, p225-232), and wound healing by anti-inflammatory effect ⁇ Genes Dev. 2001, 15, p3263-3277., Proc. Natl. Acad. Sci. USA 2003, 100, p6295- 6296) .
  • CNS central nervous system
  • PPAR ⁇ is associated with the differentiation of fat cells and the metabolism of fat (Proc. Natl. Acad. Sci. USA 2002, 99, p303-308., MoJ.
  • PPAR ⁇ activates the expression of key genes associated with ⁇ -oxidation and uncoupling proteins (UCPs) associated with energy metabolism, in a fatty acid degradation process
  • UCPs ⁇ -oxidation and uncoupling proteins
  • PPAR ⁇ makes it possible to increase HDL levels and improve type II diabetes without changing bodyweight and (Proc. Natl. Acad. Sci. USA 2001, 98, p5306-5311., 2003, 200, pl5924-
  • the regulation of fat metabolism by PPAR ⁇ provides an important solution required to treat obesity, diabetes, hyperlipidemia and arteriosclerosis.
  • PPAR ⁇ LBD As a result of examining the crystal structure of PPAR ⁇ LBD in further detail, it consists of 13 ⁇ -helixes and 4 small ⁇ - strands, and its ligand-binding pocket is Y-shaped and has a size of about 1300 A 3 . It can be seen that the entrance of the ligand-binding pocket is about 100 A 2 in size, and its periphery consists of polar amino acids.
  • the binding assay of natural eicosapentaenoic acid (EPA) and synthetic ligand GW2433 showed that the Y473 amino acid at the AF-2 site of crystal structure of PPAR ⁇ makes a hydrogen bond with the carboxylic acid of the ligand (Proc. Natl. Acad. Sci.
  • a selective ligand developed in the first stage is L-631033 reported by the research team of Merk Co. (J. Steroid Biochem. MoI. Biol. 1997, 63, pl-8), in which the L-631033 ligand was made by introducing a functional group capable of fixing a side chain, based on the structure of natural fatty acids. Also, the same research team reported more effective ligand L-165041 (J. Med. Chem. 1996, 39, p2629-2654), which is a compound already known as a leukotriene agonist which acts also as an activator on human PPAR ⁇ .
  • This ligand was reported to be spatially well bound to the ligand-binding pocket, since it has a Y-shaped structure containing a benzene structure, unlike ligands developed so far. However, this ligand is a double-activating ligand showing activity also for hPPAR ⁇ and showed reduced selectivity for PPAR ⁇ .
  • PPAR ⁇ -selective ligand GW501516 [2- methyl-4-[ [ [4-methyl-2- [ 4- (trifluoromethyl) phenyl] -1, 3- thiazol-5-yl]methyl] sulfanyl] phenoxy] acetic acid) recently developed by Glaxo-Smith-Kline Co.
  • the ligand GW501516 had a very good affinity (1-10 nM) for PPAR ⁇ and showed a 1000-fold higher selectivity for PPAR ⁇ and
  • the present invention relates to novel thiazole derivatives represented by Formula I, as peroxisome proliferator-activated Receptor ⁇ (PPAR ⁇ ) -activating ligands, which can be used for the treatment of obesity, hyperlipidemia, arteriosclerosis and diabetes, as well as their intermediates and preparation methods thereof:
  • PPAR ⁇ peroxisome proliferator-activated Receptor ⁇
  • A is hydrogen, R 2 or ;
  • Ri is a hydrogen atom, a Ci- 4 alkyl group, a Ci_ 4 alkyloxy group, a Ci-4 alkylthioxy group, a Ci_ 4 alkylamine group, a fluorine atom or a chlorine atom;
  • M is an integer from 0 to 4;
  • R 2 is a phenol-protecting group selected from among C 1 - 4 lower alkyl groups, allyl groups, alkylsilyl groups, alkylarylsilyl groups and a tetrahydropyranyl group;
  • R 3 groups are different from each other and denote a hydrogen atom, a halogen atom, or a C 1 - 4 alkyl or alkoxy group substituted or unsubstituted with halogen;
  • N is an integer from 0 to 5;
  • R 5 is a hydrogen atom, a hydroxyl group or a Ci_ 4 alkyl group
  • Re is a carboxylic acid protecting group having C 1 -4 alkyl, an allyl group, a hydrogen atom or an alkali metal
  • Rn is an arylaminoalkyl group or an alkylaminoalkyl group
  • R 12 is a halogen atom, a cyano group, or a C 1 -4 alkyl or alkoxy group substituted or unsubstituted with halogen;
  • Ri 3 is a hydrogen atom, a halogen atom, a cyano group, a C x - 4 alkyl or alkoxy group substituted or unsubstituted with halogen;
  • o, p and q are each independently an integer from 1 to 5; and r is an integer from 1 to 9.
  • the thiazole derivative compounds according to the present invention include racemates or optical isomers represented by Formulas VI, VII and IX, and compounds of
  • Ri, R 3 to R 5 , m and n have the same meanings as described in Formula I above, and R ⁇ & is a carboxylic acid protecting group having a Ci_ 4 alkyl group, or an allyl group; [Formula X]
  • Ri, R 3 to R 5 , m and n have the same meanings as described in Formula I above, and R ⁇ b is a hydrogen atom or an alkali metal.
  • the thiazole derivative compounds of Formula X according to the present invention are characterized by having activity for a peroxisome proliferator-activated receptor ⁇ (PPAR ⁇ ) .
  • PPAR ⁇ peroxisome proliferator-activated receptor ⁇
  • the novel compounds according to the present invention can be prepared through the following reaction pathways.
  • the phenol group of a 4-halogen phenol compound of Formula II as a starting material is protected with an alkylsilyl group to obtain a compound of Formula III, which is substituted with lithium and allowed to react with sulfur and a compound of Formula IV to obtain a compound of Formula V.
  • the formula V compound is allowed to react various electrophilic compounds in the presence of a strong base to synthesize compounds of Formula VI, followed by removal of the silyl protecting group from the phenol group, thus obtaining compounds of Formula VII.
  • the phenol group of the formula II compound is protected with a Grignard reagent, and the halogen of the compound is substituted with lithium, and the resulting compound is allowed to react with sulfur and a compound of Formula IV to form thioether.
  • the formula VII compounds thus obtained are allowed to react with alkyl halogen acetate of Formula VIII in the presence of inorganic salt to synthesize compounds of Formula IX, followed by ester hydrolysis, so as to obtain compounds of Formula X.
  • the present invention has been completed.
  • Ri is a hydrogen atom, a C 1 -4 alkyl group, a C1-4 alkyloxy group, a Ci_ 4 alkylthioxy group, a C 1 -4 alkylamine group, a fluorine atom or a chlorine atom;
  • m is an integer from 0 to 4;
  • R. 2 is a phenol-protecting group selected from among C 1 - 4 lower alkyl groups, allyl groups, alkylsilyl groups, alkylarylsilyl groups and a tetrahydropyranyl group;
  • R 3 groups are different from each other and denote a hydrogen atom, a halogen atom, or a Ci- 4 alkyl or alkoxy group substituted or unsubstituted with halogen;
  • n is an integer from 0 to 5;
  • R 5 is a hydrogen atom, a hydroxyl group, or a Ci- 4 alkyl group
  • R 6 is a carboxylic acid protecting group having Ci_ 4 alkyl, allyl group, a hydrogen atom or an alkali metal;
  • Rn is an arylaminoalkyl group or an alkylaminoalkyl group;
  • Ri 2 is a halogen atom, a cyano group, or a Ci- 4 alkyl or alkoxy group substituted or unsubstituted with halogen
  • Ri 3 is a hydrogen atom, a halogen atom, a cyano group, or a Ci- 4 alkyl or alkoxy group substituted or unsubstituted with halogen
  • o, p and q are each independently an integer from 1 to 5
  • r is an integer from 1 to 9.
  • an object of the present invention is to provide novel PPAR ⁇ -activating ligands represented by Formula X, which can be used as agents for treating obesity, hyperlipidemia, arteriosclerosis and diabetes.
  • Another object of the present invention is to provide a method for preparing compounds of Formula VI, which comprises reacting a compound of Formula II with a phenol-protecting group to obtain a compound of Formula III, subjecting the formula III compound to halogen-lithium substitution, reacting the resulting compound with sulfur (S) and a compound of Formula IV without separation and purification so as to prepare a compound of Formula V, reacting the formula V compound with a strong base and then with various electrophilic compounds.
  • Still another object of the present invention is to provide a method for preparing compounds of Formula VII by removing the phenol-protecting group from the compounds of Formula VI .
  • Still another object of the present invention is to provide a method for preparing compounds of Formula VII through a single process in a convenient manner, the method comprising protecting the phenol group of a phenolic compound of Formula II with a Grignard reagent without conducting a special reaction for introducing a protecting group, subjecting the protected compound to halogen-to-lithium substitution, reacting the resulting compound with sulfur (S) and then with a compound of Formula IV to prepare a thioether compound, and reacting the thioether compound with a strong base and electrophilic compounds.
  • Still another object of the present invention is to provide a method for preparing compounds of Formula IX, comprising reacting the compounds of Formula VII with alkyl halogen acetate and inorganic salt.
  • Still another object of the present invention is to provide a method for preparing compounds of Formula X by hydrolyzing the ester compounds of Formula IX.
  • Ri denotes a hydrogen atom, a Ci- 4 alkyl group, a Ci- 4 alkyloxy group, a Ci_ 4 alkylthioxy group, a C 1 - 4 alkylamine group, a fluorine atom or a chlorine atom.
  • Each of Ri groups is at an ortho or meta position with respect to the phenol group, and the number (m) of R 1 groups is 0-4.
  • R 2 is a phenol-protecting group, such as C 1 - 4 lower alkyl, allyl, alkylsilyl or alkylarylsilyl such as trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl or tert-butyldimethylsilyl, or tetrahydropyranyl.
  • R 2 is a phenol-protecting group, such as C 1 - 4 lower alkyl, allyl, alkylsilyl or alkylarylsilyl such as trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl or tert-butyldimethylsilyl, or tetrahydropyranyl.
  • these protecting groups preferred is tert-butyl, tetrahydropyranyl, or a silylated protecting group.
  • R 3 groups are different from each other and denote a hydrogen atom, a halogen atom or a C 1 - 4 alkyl or alkoxy group substituted or unsubstituted with halogen, and the number (n) of R 3 groups is 0-5.
  • R 4 denotes , O' R " , O r
  • R 5 denotes a hydrogen atom, a hydroxyl group or a C ⁇ - 4 alkyl group.
  • R 6 is a carboxylic acid protecting group having a C 1 - 4 alkyl group (e.g., methyl, ethyl, n-propyl, iso-propyl, n- butyl, sec-butyl or tert-butyl), an allyl, a hydrogen atom or an alkali metal (Li + , Na + , K + ) .
  • Rn is an arylaminoalkyl group, such as methyl pridinyl amino ethyl, methyl phenyl amino ethyl, or t-butyl phenyl amino ethyl, or an alkylaminoalkyl group, such as methyl amino ethyl, t-butyl amino ethyl or ethyl amino propyl.
  • Ri 2 is a halogen atom, a cyano group or a C 1 -4 alkyl or alkoxy group substituted or unsubstituted with halogen.
  • Ri 3 is a hydrogen atom, a halogen atom, a cyano group or a Ci- 4 alkyl or alkoxy group substituted or unsubstituted with halogen.
  • o, p and q are each independently an integer from 1 to 5.
  • r is an integer from 1 to 9.
  • Xi is a halogen atom, such as a bromine atom (Br) and a iodine atom (I) .
  • X 2 denotes a leaving group in nucleophilic reaction.
  • the leaving group conventional leaving groups can be used, for example, halogen atoms, such as chlorine, bromine or iodine, methanesulfonyloxy (MsO ' ) and p-toluenesulfonyloxy (TsO " ) .
  • halogen atoms such as chlorine, bromine or iodine
  • MsO ' methanesulfonyloxy
  • TsO " p-toluenesulfonyloxy
  • X 3 denotes a leaving group.
  • the leaving group conventional leaving groups, for example, halogens, methanesulfonyloxy (MsO " ) and p-toluenesulfonyloxy (TsO ⁇ ) , can be used.
  • the halogens include fluorine, chlorine, bromine and iodine. Among these leaving groups, preferred are halogens, and more preferred are chlorine, bromine and iodine .
  • X 4 denotes a halogen atom, such as chlorine (Cl) , bromine (Br) or iodine (I) .
  • the compounds of Formulas (I) and (II) and the electrophilic compounds, used as raw materials or intermediates in the preparation method according to the present invention, are known compounds which can be commercially easily available or easily prepared according to the literature.
  • a compound represented by Formula II is preferably allowed to react with a compound conventionally used as a phenol protecting group, in the presence of a base.
  • Non-protonic polar solvents which can be used in this step may include N 1 N-dimethylformamide, N, W-dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethyl acetate, carbon tetrachloride, chloroform and dichloromethane .
  • Ether solvents which can be used in this step may include tetrahydrofuran, dioxane, dimethoxyethane, diethyleneglycoldimethylether and triethyleneglycoldimethylether .
  • Aromatic hydrocarbons may include benzene, toluene and xylene. Among these solvents, preferred are non-protonic polar solvents, and more preferred are N,N-dimethylformamide, chloroform and dichloromethane .
  • Bases which can be used in this step include amine bases, such as pyridine, triethylamine, imidazole and N,N- dimethylaminopyridine, and if alkyl or allylether is used as the protecting group, sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate will be used as the base.
  • amine bases such as pyridine, triethylamine, imidazole and N,N- dimethylaminopyridine
  • alkyl or allylether alkyl or allylether is used as the protecting group
  • sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate will be used as the base.
  • preferred bases are imidazole and potassium carbonate.
  • the tetrahydropyranyl-protecting group is obtained by reacting 3, 4-dihydro-2H-pyran with alkyl or allyltriphenylphosphonium bromide in the presence of a catalyst.
  • the reaction temperature may vary depending on the kind of solvent used, but is generally -10 to 80 0 C, and preferably 0 to room temperature (25 °C) .
  • the reaction time may vary depending on the reaction temperature and the kind of solvent used, but is generally 1 hour to 1 day, and preferably 4 hours or shorter.
  • a compound represented by Formula V is obtained in a single process by subjecting the compound of Formula III to halogen-to-lithium substitution, sulfur introduction and then reaction with a compound of Formula IV.
  • Anhydrous solvents which can be used in this step include diethylether, tetrahydrofuran, hexane, heptane and a mixture of two or more thereof.
  • the most preferred solvents are diethylether, tetrahydrofuran and a mixed solvent of diethylether and tetrahydrofuran.
  • Metal reagents which can be used in the halogen-to- metal substitution reaction include metals, such as lithium metal and magnesium metal, and organic metal reagents, such as n-butyllithium, sec-butyllithiuna and tert-butyllithium. Among these reagents, preferred are the organic metal reagents, and more preferred are n-butyllithium and tert- butyllithium.
  • the reaction temperature may vary depending on the kind of solvent used, but is generally -100 to 25 °C, and preferably -75 0 C to room temperature for the halogen-to- lithium substitution and the sulfur introduction reaction, and room temperature (25 0 C) for the reaction with the compound of Formula III.
  • the reaction time may vary depending on the reaction temperature and the kind of solvent used, but is generally 30 minutes to 4 hours, and preferably 1 hour or shorter.
  • a compound represented by Formula VI is obtained by treating the ⁇ -proton of thioether of the compound of Formula V with a strong base to prepare a nucleophile which is then allowed to react with various electrophilic compounds.
  • Anhydrous solvents which can be used in this step include diethylether, tetrahydrofuran, hexane, heptane, and a mixture of two or more thereof. Among these solvents, preferred solvents are diethylether, tetrahydrofuran and a mixed solvent of diethylether and tetrahydrofuran.
  • Strong base reagents which can be used in the alpha- hydrogen extraction reaction include potassium tert-butoxide (t-BuOK) , lithium diisopropylamide (LDA) , n-butyllithium, sec-butyllithium and tert-butyllithium. Among these reagents, the most preferred is tert-butyllithium.
  • the electrophilic compounds that react with the nucleophilic thioether compound are known compounds which can be commercially easily available or easily prepared according to the literature and contain halogen, aldehyde or ketone. These compounds are added for reaction after dissolution in anhydrous solvent or without dissolution.
  • the reaction temperature may vary depending on the kind of solvent used, but is generally -78 to 25 0 C.
  • the alpha-hydrogen extraction with the strong base is conducted at -75 0 C, and the electrophilic compounds are added at -75 0 C and reacted while elevating the temperature slowly to room temperature (25 °C) .
  • the reaction time may vary depending on the reaction step, but is 10-30 minutes for the alpha-hydrogen extraction with the strong base and 30-90 minutes for the reaction with the electroophilic compounds.
  • a compound of Formula VII is obtained by removing the phenol-protecting group from the compound of Formula VI.
  • Polar solvents which can be used in this step include N f iV-dimethylformamide, N, N-dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethylacetate, carbon tetrachloride, chloroform and dichloromethane .
  • Ether solvents may include tetrahydrofuran, dioxane, dimethoxyethane and diethyleneglycoldimethylether .
  • Alcohol solvents may include methanol and ethanol.
  • Aromatic hydrocarbons may include benzene, toluene and xylene. Among these solvents, preferred are the polar solvents, and the most preferred is tetrahydrofuran.
  • Lewis acids such as trimethylsilyl iodide, sodium ethane thioalcohol, lithium iodide, aluminum halide, boron halide and trifluoroacetic acid are used to remove protecting groups, such as methyl, ethyl, tert-butyl, benzyl and allylether.
  • fluorides such as tetrabutylammonium fluoride (Bu 4 N + F-) , halogenic acids (fluoric acid, hydrochloric acid, bromic acid and iodic acid) , potassium fluoride are used to remove silylated protecting groups, such as trimethylsilyl, tert- butyldiphenylsilyl, triisopropylsilyl and tert- butyldimethylsilyl .
  • silylated protecting groups such as trimethylsilyl, tert- butyldiphenylsilyl, triisopropylsilyl and tert- butyldimethylsilyl .
  • the reaction temperature may vary depending on the kinds of deprotecting group and solvent used, but is generally 0-120 0 C and preferably 10-25 0 C.
  • the reaction time may vary depending on the reaction time, but is generally 30 minutes to 1 day, and preferably 2 hours or shorter.
  • Anhydrous solvents which can be used in this step include diethylether, tetrahydrofuran, hexane, heptane and a mixed solvent of two or more thereof.
  • diethylether, tetrahydrofuran or a mixed solvent of diethylether and tetrahydrofuran are preferred.
  • a Grignard reagent used is methyl, ethyl, n-propyl, iso- propyl, n-butyl, sec-butyl magnesium chloride (R 2 MgCl) or alkyl magnesium bromide (R 2 MgBr) .
  • R 2 MgCl sec-butyl magnesium chloride
  • R 2 MgBr alkyl magnesium bromide
  • the most preferred is iso-propyl magnesium chloride (CH 3 JaCHMgCl).
  • the reaction temperature may vary depending on the kind of solvent used, but is generally -20 to 40 0 C, and preferably 0 0 C to room temperature (25 0 C) .
  • the reaction time may vary depending on the reaction temperature and the kind of solvent used, but is generally 10-60 minutes, and preferably 10-30 minutes.
  • Organic metal reagents which can be used in halogen-to- lithium substitution reaction include n-butyllithium, sec- butyllithium and tert-butyllithium. Among these metal reagents, preferred is tert-butyllithium.
  • S is preferably in the form of fine particle powder and is added for reaction after dissolution in an anhydrous tetrahydrofuran solvent or without dissolution.
  • the reaction temperature may vary depending on the kind of solvent used, but is generally -78 to 25 °C, and preferably -75 0 C for the halogen-to-metal substitution reaction, and room temperature (25 °C) starting from -75 °C for the sulfur introduction reaction.
  • the reaction temperature is 10-30 minutes for the halogen-to-metal substitution reaction and 30-90 minutes for the sulfur introduction reaction.
  • halogen in the formula IV compound include chlorine, bromine and iodine. Among these halogens, preferred is chlorine.
  • the reaction temperature may vary depending on the kind of solvent used, but is generally -78 °C to 25 0 C, and preferably 0 0 C to 10 0 C.
  • the reaction time is generally 10- 120 minutes, and preferably 10-60 minutes.
  • Strong bases which can be used to treat the ⁇ -proton of thioether to prepare nucleophilic compounds include potassium tert-butoxide (t-BuO ⁇ K + ) , lithium diisopropyl amide (LDA) , n- butyllithium, sec-butyllithium and tert-butyllithium.
  • t-BuO ⁇ K + potassium tert-butoxide
  • LDA lithium diisopropyl amide
  • n- butyllithium n- butyllithium
  • sec-butyllithium sec-butyllithium
  • tert-butyllithium is most preferable.
  • the electrophilic compound that reacts with nucleophilic thioether compounds is a known compound which is commercially easily available or easily prepared according to the literature and contains highly reactive halogen, aldehyde or ketone. This compound is added for reaction after dissolution in anhydrous solvent or without dissolution.
  • the reaction temperature may vary depending on the kind of solvent used, but is generally -78 to 25 0 C.
  • the alpha-hydrogen extraction with the strong base is carried out at -75 0 C, and the electrophilic compounds are added at - 75 °C and allowed to react while elevating the temperature to room temperature (25 0 C) .
  • the reaction time varies depending on the reaction step, but is 10-30 minutes for the alpha- hydrogen extraction with the strong base, and 30-90 minutes for the reaction with the electrophilic compounds.
  • Step F Preparation of compound represented by Formula IX
  • a compound represented by Formula VII is preferably allowed to react with halogen acetic acid alkyl ester in the presence of a base.
  • the halogen acetic acid alkyl ester is a known compound which is commercially easily available and in which the halogen is chlorine, bromine or iodine.
  • the most preferred example of the halogen acetic acid alkyl ester is bromoacetic acid methyl ester or bromoacetic acid ethyl ester.
  • Solvents which can be used in this step include water- soluble solvents, such as N, N-dimethylformamide, N, N- dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethanol and methanol, or a mixture of any one thereof with 1- 10% water.
  • water- soluble solvents such as N, N-dimethylformamide, N, N- dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethanol and methanol, or a mixture of any one thereof with 1- 10% water.
  • solvents the most preferred is a mixture of acetone or dimethylsulfoxide with 1-5% water.
  • the base used is not specifically limited regardless of a strong base or weak base as long as it does not adversely affects the reaction, and examples thereof include alkali metal hydrides, such as sodium hydride and lithium hydride, alkaline earth metal hydride such as potassium hydride, alkali metal hydroxides, such as sodium hydroxide and potassium hydroxide, and alkali metal carbonates, such as lithium carbonate, potassium carbonate, potassium hydrogen carbonate and cesium carbonate.
  • alkali metal hydrides such as sodium hydride and lithium hydride
  • alkaline earth metal hydride such as potassium hydride
  • alkali metal hydroxides such as sodium hydroxide and potassium hydroxide
  • alkali metal carbonates such as lithium carbonate, potassium carbonate, potassium hydrogen carbonate and cesium carbonate.
  • alkali metal carbonate preferred is alkali metal carbonate, and more preferred is potassium carbonate .
  • the reaction temperature is not specifically limited as long as it is below the boiling point of a solvent used, but a reaction at a relatively high temperature is preferably avoided in order to suppress side reactions.
  • the reaction temperature is generally 0-60 0 C.
  • the reaction temperature may vary depending on the reaction temperature, but is generally 30 minutes to 1 day, and preferably 30-90 minutes.
  • a compound represented by Formula X is prepared by hydrolyzing the carboxylic ester of the compound of Formula IX with a water-soluble inorganic salt in alcohol solvent.
  • Solvents which can be used in this step include water- soluble alcohol solvents, such as methanol and ethanol.
  • Bases which can be used in this step include about 0.1-3 N aqueous solutions prepared using alkali metal hydroxides, such as lithium hydroxide, sodium hydroxide and potassium hydroxide, according to the form of carboxylic acid alkali salts.
  • alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide
  • acetic acid or 0.1-3 ⁇ J hydrochloric acid aqueous solution is preferably used.
  • the reaction is preferably carried out at a relatively low temperature in order to inhibit side reactions, and is generally at 0 °C to room temperature.
  • the reaction time may vary depending on the reaction temperature, but is generally 10 minutes to 3 hours, and preferably 30 minutes to 1 hour.
  • Sep G-2 Preparation of compound represented by Formula X_
  • a compound represented by Formula X is prepared by substituting the allyl ester of the compound of Formula IX with a metal salt of 2-ethylhexanoate in an organic solvent in the presence of a metal catalyst.
  • the solvent used in this step is an anhydrous organic solvents, such as chloroform, dichloromethane or ethyl acetate. ⁇
  • palladium tetrakistriphenylphosphin is preferably used in an amount of 0.01-0.1 equivalent.
  • the reaction is preferably carried out at a relatively low temperature in order to inhibit side reactions, and is generally conducted at 0 °C to room temperature.
  • the reaction time may vary depending on the reaction temperature, but is generally 10 minutes to 3 hours, and preferably 30 minutes to 1 hour.
  • This salt compound is separated with high purity by centrifugation.
  • the obtained metal salt-type compound of Formula X is easier to separate than the salt-type compound prepared using the step G-I (hydrolysis step) .
  • the Y-shaped thiazole compounds of Formula X thus obtained are important substances as ligands for PPAR ⁇ . Also, these compounds have chiral carbon, and so stereoisomers thereof exist. Among the compounds of Formula X, R-form or S-form isomers are confirmed to be effective compared to racemates, and the scope of the present invention encompasses the compounds of Formula X, and their stereoisomers, solvates and salts.
  • the novel thiazole derivative compounds according to the present invention have the characteristics of PPAR ⁇ -activating ligands and show a high possibility to be used as agents for treating cardiovascular disease, lowering cholesterol levels and treating diabetes and obesity. Also, the inventive preparation method is useful for the preparation of the thiazole derivative compounds .
  • Example 4 Preparation of 5- [1- [3-methyl-4- ( tert- butyldimethylsilyloxy) phenylthio] -3-phenylpropyl] -2- [4- (trifluoromethyl) phenyl] -4-methylthiazole (VI) [Step C] In a nitrogen atmosphere, 510 mg (1.0 mmol) of 5- [4- ( tert-butyldimethylsilanyloxy) -3-methyl- phenylsulfanylmethyl] -4-methyl-2- [ (4-trifluoromethyl) phenyl] - thiazole prepared in Example 3 was dissolved in 20 ml of anhydrous tetrahydrofuran.
  • reaction solution was sufficiently cooled to -78 0 C, to which 1.2 ml (2.0 equivalents) of tert-butyllithium (1.7 M-heptane solution) was then slowly added. While the reaction solution maintained a deep blue color, 137 ⁇ l (1.0 mmol) of (2- bromoethyl) benzene was added thereto, and the reaction temperature was slowly elevated to room temperature. After reduction for an additional time of about 30 minutes, the reaction was terminated with aqueous ammonium chloride solution, and the reaction product was extracted wit ethyl acetate and aqueous salt solution, and the organic layer was dried over magnesium sulfate.
  • reaction product was extracted with aqueous ammonium chloride solution and ethyl acetate, and the organic layer was dried over magnesium sulfate. After filtration, the solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography, thus obtaining 306 mg (94 % yield) of the title compound.
  • Example 39 Preparation of 4- [2- (2-chloro-6- fluorophenyl) -1- [2- [4- (trifluoror ⁇ ethyl) phenyl] -A- methylthiazol-5-yl] ethylthio] -2-methylphenol (VII) from compound of Formula II [Step E]
  • 585 mg (2.5 mmol) of 4-iodo- 2-methylphenol was dissolved in 35 ml of anhydrous tetrahydrofuran and maintained at a temperature of 0 0 C.
  • 1.3 ml (1.0 equivalent) of isopropyl magnesium chloride (2 M-ether solution) was slowly added and the mixture was allowed to react for 10 minutes.
  • Test Example 1 Activity and cytotoxicity tests The compounds prepared in Examples were tested for PPAR ⁇ activity by a transfection assay. In addition, the compounds were tested for selectivity for PPAR ⁇ and PPAR ⁇ , the subtypes of PPARs, and also tested for toxicity by a MTT assay.
  • Transfection assay A transfection assay was performed using CV-I cells. The culture of the cells was performed using a DMEM medium (10% FBS, DBS (delipidated) and 1% penicillin/streptomycin) on a 96-well plate in a 5% carbon dioxide-containing incubator at 37 °C. The test was performed in four steps consisting of cell inoculation, transfection, treatment of the compounds, and analysis of results. Specifically, CV-I cells were inoculated onto a 96-well plate at a concentration of 5,000 cells/well, and after 24 hours, the cells were transfected.
  • DMEM medium % FBS, DBS (delipidated) and 1% penicillin/streptomycin
  • PPARs plasmid DNA full-length PPARs plasmid DNA, reporter DNA that has luciferase activity and thus allows the identification of PPARs, and ⁇ -galactosidase DNA that provides the information of transfection efficiency.
  • DMSO dimethylsulfoxide
  • the cells were cultured in an incubator for 24 and then lysed with lysis buffer. The lysed cells were measured for luciferase and ⁇ -galactosidase activities using a luminometer and a microplate reader. The measured luciferase values were normalized with the ⁇ - galactosidase values and graphed. From the graph, EC 50 values were determined.
  • MTT assay The compounds of Examples 47-97 according to the present invention were tested for cytotoxicity using a MTT assay.
  • MTT is a water-soluble yellow substance, but if it is introduced into living cells, it will be degenerated into a water-insoluble purple crystal due to dehydrogenase contained in mitochondria. If this substance is dissolved in dimethylsulfoxide and then measured for absorbance at 550 nm, cytotoxicity can be assayed.
  • the test method is as follows.
  • CV-I cells were first inoculated onto a 96-well plate at a concentration of 5,000 cells/well.
  • the inoculated cells were cultured in a 5% carbon dioxide-containing humidified incubator at 37 0 C for 24 hours, and then treated with the inventive compounds at various concentrations.
  • a MTT reagent was added to the cultured cells.
  • the resulting purple crystal was dissolved in dimethylsulfoxide and then measured for absorbance using a microplate reader. From the measured absorbance, cytotoxicity was assayed.
  • test results showed that most of the inventive compounds had no cytotoxicity even at a concentration of 90 ⁇ M.
  • the present invention provides novel thiazole derivatives as peroxisome proliferator-activated receptor ⁇
  • PPAR ⁇ PPAR ⁇ -activating ligands, which can be used for treatment of obesity, hyperlipidemia, arteriosclerosis and diabetes, as well as their intermediates and preparation methods thereof.
  • the present invention is useful to provide novel thiazole derivative compounds as PPAR ⁇ -activating ligands.

Abstract

The present invention relates to novel thiazole derivative compounds having activity for peroxisome prolif erator-activated receptor δ (PPARδ), as well as their intermediates and synthesis methods thereof .

Description

THIAZOLE DERIVATIVES AS PPAR DELTA LIGANDS AND THEIR MANUFACTURING PROCESS
Technical Field The present invention relates to novel thiazole derivatives represented by Formula I, as peroxisome proliferator-activated receptor δ (PPAR δ) -activating ligands, which can be used for the treatment of obesity, hyperlipidemia, arteriosclerosis and diabetes, as well as their intermediates and preparation methods thereof: [Formula I]
wherein A is hydrogen, R2 or " ORe
Background Art
Of nuclear receptors, a peroxisome proliferator- activated receptor (PPAR) includes three subtypes: PPARα, PPARγ, PPARδ {Nature, 1990, 347, p645-650., Proc. Natl. Acad. Sci. USA 1994, 91, p7335-7359). PPARα, PPARγ and PPARδ have functions distinguished according to in vivo tissues and are expressed in different sites. PPARα is expressed mainly in the human heart, kidneys, skeletal muscle and colon {Mol. Pharmacol. 1998, 53, pl4-22., Toxicol. Lett. 1999, 110, pll9- 127., J. Biol. Chem. 1998, 273, pl6710-16714) , and is associated with the β-oxidation of peroxisome and mitochondria {Biol. Cell. 1993, 77, p67-76., J. Biol. Chem. 1997, 272, p27307-27312) . PPARγ is known to be expressed weakly in a skeletal muscle, but expressed largely in fat tissue, and thus involved in the differentiation of fat cells, the storage of energy in the form of fat, and the regulation of homeostasis of insulin and sugar {Moll. Cell. 1999, 4, p585-594., p597-609., pβll-617). PPARδ has been evolutionally conserved in Vertebrata, such as mammals, including human beings, rodents and Ascidiacea. Those found so far have been known as PPARβ in Xenopus laevis {Cell 1992, 68, p879-887), and as NUCI {Mol. Endocrinol. 1992, 6, pl634~ 1641), PPARδ (Proc. Natl. Acad. Sci. USA 1994, 91, p7355- 7359), NUCI {Biochem. Biophys . Res. Commun. 1993, 196, p671- 677), FAAR (J. Bio. Chem. 1995, 270, p2367-2371) and the like, human beings, but these names were recently standardized as PPARδ. In human beings, PPARδ is known to be present in chromosome 6ρ21. l-p21.2, whereas, in rats, the mRNA of PPARδ is found in the cells of various sites, but the amount thereof is shown to be lower than that of PPARcx and PPARγ {Endocrinology 1996, 137, p354-366., J. Bio. Chem. 1995, 270, p2367-2371., Endocrinology 1996, 131, p354-366) . According to study results so far, PPARδ is known to play an important in an expression process {Genes Dev. 1999, 13, pl561-1574. ) , and to perform physiological functions, including the differentiation of nervous cells in the central nervous system (CNS) (J. Chem. Neuroanat 2000, 19, p225-232), and wound healing by anti-inflammatory effect {Genes Dev. 2001, 15, p3263-3277., Proc. Natl. Acad. Sci. USA 2003, 100, p6295- 6296) . Recent studies demonstrated that PPARδ is associated with the differentiation of fat cells and the metabolism of fat (Proc. Natl. Acad. Sci. USA 2002, 99, p303-308., MoJ.
Cell. Biol. 2000, 20, p5119-5128) , and it was found that
PPARδ activates the expression of key genes associated with β-oxidation and uncoupling proteins (UCPs) associated with energy metabolism, in a fatty acid degradation process
(Nature 2000, 406, p415-418., Cell 2003, 113, pl59-170., PLoS
Biology 2004, 2, pl532-1539) . Furthermore, the activation of
PPARδ makes it possible to increase HDL levels and improve type II diabetes without changing bodyweight and (Proc. Natl. Acad. Sci. USA 2001, 98, p5306-5311., 2003, 200, pl5924-
15929) and to suppress arteriosclerosis-associated genes so as to treat arteriosclerosis {Science, 2003, 302, ρ453-457) .
Accordingly, the regulation of fat metabolism by PPARδ provides an important solution required to treat obesity, diabetes, hyperlipidemia and arteriosclerosis.
The crystal structure of Apo-PPARδ LBD was determined on the basis of the already known structure of PPARγ (Nature 1998, 395, pl37-143) and it was reported that the structure of LBD was interestingly similar between PPAR δ and PPARγ, and particularly, the size of ligand-binding pockets was substantially equal between the two PPARs (MoI. Cell. 1999, 3, p397-403). However, different ligands selective according to the pocket shape will bind to the PPARs, and therefore a difference in function between the PPARs will be shown. As a result of examining the crystal structure of PPARδ LBD in further detail, it consists of 13 α-helixes and 4 small β- strands, and its ligand-binding pocket is Y-shaped and has a size of about 1300 A3. It can be seen that the entrance of the ligand-binding pocket is about 100 A2 in size, and its periphery consists of polar amino acids. The binding assay of natural eicosapentaenoic acid (EPA) and synthetic ligand GW2433 showed that the Y473 amino acid at the AF-2 site of crystal structure of PPARδ makes a hydrogen bond with the carboxylic acid of the ligand (Proc. Natl. Acad. Sci. USA 2001, 98, pl3919-13924) . This is supported by the fact that one side of the structure of most PPARδ-activated ligands consists of a functional group that can make a hydrogen bond. Accordingly, it can be inferred that the binding of a co- activator associated with PPARδ is well kept by the stabilization of the hydrogen bond between the AF-2 helix and the ligand. From the crystal structure of the ligand-binding pocket of PPARδ, it also was found that the active ligand requires a hydrophobic functional group at the other side. As a result, it is inferred that, due to the size of the ligand-binding pocket of PPARδ, various types of ligands can be bound and therefore show a difference in the activation thereof {Nature 1998, 391, p79-82) .
In the case of PPARδ, the development of highly selective synthetic ligands was relatively insufficient compared to PPARα and PPARγ. A selective ligand developed in the first stage is L-631033 reported by the research team of Merk Co. (J. Steroid Biochem. MoI. Biol. 1997, 63, pl-8), in which the L-631033 ligand was made by introducing a functional group capable of fixing a side chain, based on the structure of natural fatty acids. Also, the same research team reported more effective ligand L-165041 (J. Med. Chem. 1996, 39, p2629-2654), which is a compound already known as a leukotriene agonist which acts also as an activator on human PPARδ. This substance showed a 10-fold higher selectivity for hPPARδ than PPARα and PPARγ, and had an EC50 value of 530 nM. However, in a test on rodents, it had almost no selectivity for PPARγ. Other ligands L-796449 and L-783483 had a significantly improved affinity (EC50=7.9 nM) , but showed no selectivity for other hPPAR subtypes. The research team of Glaxo-Smith-Kline Co. reported PPARα activator GW2433 a Y-shaped ligand having a crystal structure similar to that of the PPARδ ligand pocket (Chem. Biol. 1997, 4, p909-918). This ligand was reported to be spatially well bound to the ligand-binding pocket, since it has a Y-shaped structure containing a benzene structure, unlike ligands developed so far. However, this ligand is a double-activating ligand showing activity also for hPPARα and showed reduced selectivity for PPARδ. PPARδ-selective ligand GW501516 ( [2- methyl-4-[ [ [4-methyl-2- [ 4- (trifluoromethyl) phenyl] -1, 3- thiazol-5-yl]methyl] sulfanyl] phenoxy] acetic acid) recently developed by Glaxo-Smith-Kline Co. showed excellent physiological activity compared to the earlier developed ligand {Proc. Natl. Acad. Sci. USA 2001, 98, p5306-5311) . The ligand GW501516 had a very good affinity (1-10 nM) for PPARδ and showed a 1000-fold higher selectivity for PPARα and
PPARγ. Accordingly, it is thought that, in future experiments associated with PPARδ, an experiment based on GW501516 will be effective. However, PPARδ activities obtained by ligands developed so far are results shown by binding to 30-40% of the total region of the ligand-binding pocket . Disclosure of Invention Technical Problem
Accordingly, in order to confirm the exact effects of PPARδ on obesity, hyperlipidemia, arteriosclerosis and diabetes, there is a need for the development of novel ligands having a shape similar to a ligand-binding pocket and showing high selectivity and activity, as well as an economically advantageous preparation method thereof.
Technical Solution
The present invention relates to novel thiazole derivatives represented by Formula I, as peroxisome proliferator-activated Receptor δ (PPARδ) -activating ligands, which can be used for the treatment of obesity, hyperlipidemia, arteriosclerosis and diabetes, as well as their intermediates and preparation methods thereof:
[Formula I]
where in A is hydrogen, R2 or ; Ri is a hydrogen atom, a Ci-4 alkyl group, a Ci_4 alkyloxy group, a Ci-4 alkylthioxy group, a Ci_4 alkylamine group, a fluorine atom or a chlorine atom; M is an integer from 0 to 4; R2 is a phenol-protecting group selected from among C1-4 lower alkyl groups, allyl groups, alkylsilyl groups, alkylarylsilyl groups and a tetrahydropyranyl group;
R3 groups are different from each other and denote a hydrogen atom, a halogen atom, or a C1-4 alkyl or alkoxy group substituted or unsubstituted with halogen; N is an integer from 0 to 5;
R5 is a hydrogen atom, a hydroxyl group or a Ci_4 alkyl group; Re is a carboxylic acid protecting group having C1-4 alkyl, an allyl group, a hydrogen atom or an alkali metal;
Rn is an arylaminoalkyl group or an alkylaminoalkyl group;
R12 is a halogen atom, a cyano group, or a C1-4 alkyl or alkoxy group substituted or unsubstituted with halogen; Ri3 is a hydrogen atom, a halogen atom, a cyano group, a Cx-4 alkyl or alkoxy group substituted or unsubstituted with halogen; o, p and q are each independently an integer from 1 to 5; and r is an integer from 1 to 9. The thiazole derivative compounds according to the present invention include racemates or optical isomers represented by Formulas VI, VII and IX, and compounds of
Formula X, which can be prepared from compounds of Formula
IX: [Formula VI]
wherein Ri to R5, m and n have the same meanings as described in Formula I above; [Formula VII]
wherein Ri, R3 to R5, m and n have the same meanings as described in Formula I above; [Formula IX]
wherein Ri, R3 to R5, m and n have the same meanings as described in Formula I above, and R^& is a carboxylic acid protecting group having a Ci_4 alkyl group, or an allyl group; [Formula X]
wherein Ri, R3 to R5, m and n have the same meanings as described in Formula I above, and Rβb is a hydrogen atom or an alkali metal.
The thiazole derivative compounds of Formula X according to the present invention are characterized by having activity for a peroxisome proliferator-activated receptor δ (PPARδ) . The novel compounds according to the present invention can be prepared through the following reaction pathways.
As shown in the following reaction scheme, the phenol group of a 4-halogen phenol compound of Formula II as a starting material is protected with an alkylsilyl group to obtain a compound of Formula III, which is substituted with lithium and allowed to react with sulfur and a compound of Formula IV to obtain a compound of Formula V. The formula V compound is allowed to react various electrophilic compounds in the presence of a strong base to synthesize compounds of Formula VI, followed by removal of the silyl protecting group from the phenol group, thus obtaining compounds of Formula VII. In another method, the phenol group of the formula II compound is protected with a Grignard reagent, and the halogen of the compound is substituted with lithium, and the resulting compound is allowed to react with sulfur and a compound of Formula IV to form thioether. The thioether is allowed to react with a strong base without separation and are then allowed to sequentially react with various electrophilic compounds (O=CR4-R5 or X3-CHR4R5) , whereby compounds of Formula VII can be obtained in a single process. The formula VII compounds thus obtained are allowed to react with alkyl halogen acetate of Formula VIII in the presence of inorganic salt to synthesize compounds of Formula IX, followed by ester hydrolysis, so as to obtain compounds of Formula X. Based on the finding that the compounds of Formula X can be prepared by the above-described method, the present invention has been completed. [Reaction Scheme]
wherein Ri is a hydrogen atom, a C1-4 alkyl group, a C1-4 alkyloxy group, a Ci_4 alkylthioxy group, a C1-4 alkylamine group, a fluorine atom or a chlorine atom; m is an integer from 0 to 4;
R.2 is a phenol-protecting group selected from among C1-4 lower alkyl groups, allyl groups, alkylsilyl groups, alkylarylsilyl groups and a tetrahydropyranyl group; R3 groups are different from each other and denote a hydrogen atom, a halogen atom, or a Ci-4 alkyl or alkoxy group substituted or unsubstituted with halogen; n is an integer from 0 to 5;
R5 is a hydrogen atom, a hydroxyl group, or a Ci-4 alkyl group;
R6 is a carboxylic acid protecting group having Ci_4 alkyl, allyl group, a hydrogen atom or an alkali metal; Rn is an arylaminoalkyl group or an alkylaminoalkyl group;
Ri2 is a halogen atom, a cyano group, or a Ci-4 alkyl or alkoxy group substituted or unsubstituted with halogen; Ri3 is a hydrogen atom, a halogen atom, a cyano group, or a Ci-4 alkyl or alkoxy group substituted or unsubstituted with halogen; o, p and q are each independently an integer from 1 to 5; and r is an integer from 1 to 9.
Specifically, an object of the present invention is to provide novel PPARδ-activating ligands represented by Formula X, which can be used as agents for treating obesity, hyperlipidemia, arteriosclerosis and diabetes.
Another object of the present invention is to provide a method for preparing compounds of Formula VI, which comprises reacting a compound of Formula II with a phenol-protecting group to obtain a compound of Formula III, subjecting the formula III compound to halogen-lithium substitution, reacting the resulting compound with sulfur (S) and a compound of Formula IV without separation and purification so as to prepare a compound of Formula V, reacting the formula V compound with a strong base and then with various electrophilic compounds.
Still another object of the present invention is to provide a method for preparing compounds of Formula VII by removing the phenol-protecting group from the compounds of Formula VI .
Still another object of the present invention is to provide a method for preparing compounds of Formula VII through a single process in a convenient manner, the method comprising protecting the phenol group of a phenolic compound of Formula II with a Grignard reagent without conducting a special reaction for introducing a protecting group, subjecting the protected compound to halogen-to-lithium substitution, reacting the resulting compound with sulfur (S) and then with a compound of Formula IV to prepare a thioether compound, and reacting the thioether compound with a strong base and electrophilic compounds.
Still another object of the present invention is to provide a method for preparing compounds of Formula IX, comprising reacting the compounds of Formula VII with alkyl halogen acetate and inorganic salt.
Still another object of the present invention is to provide a method for preparing compounds of Formula X by hydrolyzing the ester compounds of Formula IX.
Among the compounds represented by Formula X, the following compounds are novel compounds, and intermediates of Formulas V, VI, VII and IX for preparing these compounds are also novel compounds: 2- [4- [1- [2- [4- (trifluoromethyl) phenyl] - 4-methylthiazol-5-yl] -3-phenylpropylthio] -2- methylphenoxy] acetic acid, 2- [4- [1- [2- [4-
(trifluoromethyl ) phenyl] -4-methylthiazol-5-yl] -A- phenylbutylthio] -2-methylphenoxy] acetic acid, 2- [4- [1- [2- [4- (trifluoromethyl ) phenyl] -4-methylthiazol-5-yl] -5- phenylpentylthio] -2-methylphenoxy] acetic acid, 2- [4- [1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -6- phenylhexylthio] -2-methylphenoxy] acetic acid, 2- [4- [1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -8- phenyloctylthio] -2-methylphenoxy] acetic acid, 2- [4- [1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -11- phenylundecylthio] -2-methylphenoxy] acetic acid, 2- [4- [2- (2- chloro-6-fluorophenyl) -1- [2- [4- (trifluoromethyl) phenyl] -4- methylthiazol-5-yl] ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [2- (4-cyanophenyl) -1- [2- [4- (trifluoromethyl) phenyl] -A- methylthiazol-5-yl] ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -2- (naphthalene-3-yl) ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [2- [4- (trifluoromethyl) phenyl] -1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] ethylthio] -2- methylphenoxy] acetic acid, 2- [4- [1- [2- [4-
(trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -2- (3,5- dirαethoxyphenyl) ethylthio] -2-methylphenoxy] acetic acid, 2-[A- [1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -2- (perfluorophenyl) ethylthio] -2-methylphenoxy] acetic acid, 2- [A- [2- (4-bromophenyl) -1- [2- [4- (trifluoromethyl) phenyl] -A- methylthiazol-5-yl] ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [2- [2-fluoro-6- (trifluoromethyl) phenyl] -1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] ethylthio] -2~ methylphenoxy] acetic acid, 2- [4- [1- [2- [4-
(trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -2- (2, 6- difluorophenyl) ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [2- (2, 6-dichlorophenyl) -1- [2- [4- (trifluoromethyl) phenyl] -4- methylthiazol-5-yl] ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -2- (2, 4-difluorophenyl) ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] - 2- (2, 3, 4-trifluorophenyl) ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [2- (2-chloro-5-fluorophenyl) -1- [2- [4-
(trifluoromethyl) phenyl] -4-methylthiazol-5-yl] ethylthio] -2- methylphenoxy] acetic acid, 4- [3- (2-chloro-6-fluorophenyl) -2- hydroxy-1- [4-methyl-2- (4-trifluoromethyl-phenyl) -thiazol-5- yl]propylsulfanyl] -2-methyl-phenoxy] acetic acid, 4- [2- hydroxy-1- [4-methyl-2- (4-trifluoromethyl-phenyl) thiazol-5- yl] -11-phenyl-undecylsulfanyl] -2-methyl-phenoxy] acetic acid, 4- [2-hydroxy-l- [4-methyl-2- (4-trifluoromethyl-phenyl) - thiazol-5-yl] -2-phenyl-ethylsulfanyl] -2-methyl-phenoxy] acetic acid, 2- [4- [2- (2-chloro-β-fluorophenyl) -1- [2- [3-fluoro-4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] ethylthio] -2- methylphenoxy] acetic acid, 2- [4- [ 1- [2- [ 3—fluoro-4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -2- (3, 4, 5- trifluorophenyl) ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [1- [2- [3-fluoro-4- (trifluoromethyl) phenyl] -4-methylthiazol-5- yl] -2- (2-fluoro-6- (trifluoromethyl) phenyl) ethylthio] -2- methylphenoxy] acetic acid, 2- [4- [1- [2- [3-fluoro-4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -2- (2,6- difluorophenyl) ethylthio] -2-methylphenoxy] acetic acid, 2-[4- [2- (2, 6-dichlorophenyl) -1- [2- [3-fluoro-4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] ethylthio] -2- methylphenoxy] acetic acid, 2- [4- [1- [2- [3-fluoro-4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -2- (2, 4- difluorophenyl) ethylthio] -2-methylphenoxy] acetic acid, 2- [4- [2- (2-chloro-5-fluorophenyl) -1- [2- [3-fluoro-4-
(trifluoromethyl) phenyl] -4-methylthiazol-5-yl] ethylthio]-2- methylphenoxy] acetic acid, and potassium 2- [4- [2- (2-chloro-6- fluorophenyl) -1- [2- [4- (trifluoromethyl) phenyl] -4- methylthiazol-5-yl] ethylthio] -2-methylphenoxy] acetate . Accordingly, the present invention provides novel useful compounds.
In the inventive compounds, Ri denotes a hydrogen atom, a Ci-4 alkyl group, a Ci-4 alkyloxy group, a Ci_4 alkylthioxy group, a C1-4 alkylamine group, a fluorine atom or a chlorine atom. Each of Ri groups is at an ortho or meta position with respect to the phenol group, and the number (m) of R1 groups is 0-4.
R2 is a phenol-protecting group, such as C1-4 lower alkyl, allyl, alkylsilyl or alkylarylsilyl such as trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl or tert-butyldimethylsilyl, or tetrahydropyranyl. Among these protecting groups, preferred is tert-butyl, tetrahydropyranyl, or a silylated protecting group.
R3 groups are different from each other and denote a hydrogen atom, a halogen atom or a C1-4 alkyl or alkoxy group substituted or unsubstituted with halogen, and the number (n) of R3 groups is 0-5. R4 denotes , O'R" , Or
R5 denotes a hydrogen atom, a hydroxyl group or a Cχ-4 alkyl group. R6 is a carboxylic acid protecting group having a C1-4 alkyl group (e.g., methyl, ethyl, n-propyl, iso-propyl, n- butyl, sec-butyl or tert-butyl), an allyl, a hydrogen atom or an alkali metal (Li+, Na+, K+) .
Rn is an arylaminoalkyl group, such as methyl pridinyl amino ethyl, methyl phenyl amino ethyl, or t-butyl phenyl amino ethyl, or an alkylaminoalkyl group, such as methyl amino ethyl, t-butyl amino ethyl or ethyl amino propyl.
Ri2 is a halogen atom, a cyano group or a C1-4 alkyl or alkoxy group substituted or unsubstituted with halogen. Ri3 is a hydrogen atom, a halogen atom, a cyano group or a Ci-4 alkyl or alkoxy group substituted or unsubstituted with halogen. o, p and q are each independently an integer from 1 to 5. r is an integer from 1 to 9.
Xi is a halogen atom, such as a bromine atom (Br) and a iodine atom (I) .
X2 denotes a leaving group in nucleophilic reaction. As the leaving group, conventional leaving groups can be used, for example, halogen atoms, such as chlorine, bromine or iodine, methanesulfonyloxy (MsO') and p-toluenesulfonyloxy (TsO") . Among these leaving groups, preferred are chlorine and bromine.
X3 denotes a leaving group. As the leaving group, conventional leaving groups, for example, halogens, methanesulfonyloxy (MsO") and p-toluenesulfonyloxy (TsO~) , can be used. The halogens include fluorine, chlorine, bromine and iodine. Among these leaving groups, preferred are halogens, and more preferred are chlorine, bromine and iodine . X4 denotes a halogen atom, such as chlorine (Cl) , bromine (Br) or iodine (I) .
The compounds of Formulas (I) and (II) and the electrophilic compounds, used as raw materials or intermediates in the preparation method according to the present invention, are known compounds which can be commercially easily available or easily prepared according to the literature.
Hereinafter, the present invention will be described in further detail. Step A: Preparation of compound represented by Formula III
In order to obtain a compound represented by Formula III, a compound represented by Formula II is preferably allowed to react with a compound conventionally used as a phenol protecting group, in the presence of a base.
Non-protonic polar solvents which can be used in this step may include N1 N-dimethylformamide, N, W-dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethyl acetate, carbon tetrachloride, chloroform and dichloromethane . Ether solvents which can be used in this step may include tetrahydrofuran, dioxane, dimethoxyethane, diethyleneglycoldimethylether and triethyleneglycoldimethylether . Aromatic hydrocarbons may include benzene, toluene and xylene. Among these solvents, preferred are non-protonic polar solvents, and more preferred are N,N-dimethylformamide, chloroform and dichloromethane .
Bases which can be used in this step include amine bases, such as pyridine, triethylamine, imidazole and N,N- dimethylaminopyridine, and if alkyl or allylether is used as the protecting group, sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate will be used as the base. Among these bases, preferred bases are imidazole and potassium carbonate. The tetrahydropyranyl-protecting group is obtained by reacting 3, 4-dihydro-2H-pyran with alkyl or allyltriphenylphosphonium bromide in the presence of a catalyst.
The reaction temperature may vary depending on the kind of solvent used, but is generally -10 to 80 0C, and preferably 0 to room temperature (25 °C) . The reaction time may vary depending on the reaction temperature and the kind of solvent used, but is generally 1 hour to 1 day, and preferably 4 hours or shorter. Step B: Preparation of compound represented by Formula V
A compound represented by Formula V is obtained in a single process by subjecting the compound of Formula III to halogen-to-lithium substitution, sulfur introduction and then reaction with a compound of Formula IV.
Anhydrous solvents which can be used in this step include diethylether, tetrahydrofuran, hexane, heptane and a mixture of two or more thereof. Among these solvents, the most preferred solvents are diethylether, tetrahydrofuran and a mixed solvent of diethylether and tetrahydrofuran.
Metal reagents which can be used in the halogen-to- metal substitution reaction include metals, such as lithium metal and magnesium metal, and organic metal reagents, such as n-butyllithium, sec-butyllithiuna and tert-butyllithium. Among these reagents, preferred are the organic metal reagents, and more preferred are n-butyllithium and tert- butyllithium. The reaction temperature may vary depending on the kind of solvent used, but is generally -100 to 25 °C, and preferably -75 0C to room temperature for the halogen-to- lithium substitution and the sulfur introduction reaction, and room temperature (25 0C) for the reaction with the compound of Formula III. The reaction time may vary depending on the reaction temperature and the kind of solvent used, but is generally 30 minutes to 4 hours, and preferably 1 hour or shorter.
Step C: Preparation of compound represented by Formula V^
A compound represented by Formula VI is obtained by treating the α-proton of thioether of the compound of Formula V with a strong base to prepare a nucleophile which is then allowed to react with various electrophilic compounds. Anhydrous solvents which can be used in this step include diethylether, tetrahydrofuran, hexane, heptane, and a mixture of two or more thereof. Among these solvents, preferred solvents are diethylether, tetrahydrofuran and a mixed solvent of diethylether and tetrahydrofuran.
Strong base reagents which can be used in the alpha- hydrogen extraction reaction include potassium tert-butoxide (t-BuOK) , lithium diisopropylamide (LDA) , n-butyllithium, sec-butyllithium and tert-butyllithium. Among these reagents, the most preferred is tert-butyllithium.
The electrophilic compounds that react with the nucleophilic thioether compound are known compounds which can be commercially easily available or easily prepared according to the literature and contain halogen, aldehyde or ketone. These compounds are added for reaction after dissolution in anhydrous solvent or without dissolution.
The reaction temperature may vary depending on the kind of solvent used, but is generally -78 to 25 0C. Preferably the alpha-hydrogen extraction with the strong base is conducted at -75 0C, and the electrophilic compounds are added at -75 0C and reacted while elevating the temperature slowly to room temperature (25 °C) . The reaction time may vary depending on the reaction step, but is 10-30 minutes for the alpha-hydrogen extraction with the strong base and 30-90 minutes for the reaction with the electroophilic compounds.
Step D: Preparation of compound represented by Formula VII
A compound of Formula VII is obtained by removing the phenol-protecting group from the compound of Formula VI. Polar solvents which can be used in this step include Nf iV-dimethylformamide, N, N-dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethylacetate, carbon tetrachloride, chloroform and dichloromethane . Ether solvents may include tetrahydrofuran, dioxane, dimethoxyethane and diethyleneglycoldimethylether . Alcohol solvents may include methanol and ethanol. Aromatic hydrocarbons may include benzene, toluene and xylene. Among these solvents, preferred are the polar solvents, and the most preferred is tetrahydrofuran.
For removal of the phenol-protecting group, Lewis acids, such as trimethylsilyl iodide, sodium ethane thioalcohol, lithium iodide, aluminum halide, boron halide and trifluoroacetic acid are used to remove protecting groups, such as methyl, ethyl, tert-butyl, benzyl and allylether. Also, fluorides, such as tetrabutylammonium fluoride (Bu4N+F-) , halogenic acids (fluoric acid, hydrochloric acid, bromic acid and iodic acid) , potassium fluoride are used to remove silylated protecting groups, such as trimethylsilyl, tert- butyldiphenylsilyl, triisopropylsilyl and tert- butyldimethylsilyl . Among these groups for removal for the silylated protecting groups, preferred are fluorides and more preferred is tetrabutylammonium fluoride.
The reaction temperature may vary depending on the kinds of deprotecting group and solvent used, but is generally 0-120 0C and preferably 10-25 0C. The reaction time may vary depending on the reaction time, but is generally 30 minutes to 1 day, and preferably 2 hours or shorter. Step E: Preparation of compound represented by Formula VII
To obtain a compound represented by Formula VII, the phenol group of the compound represented by Formula II is protected with a Grignard reagent, and the protected compound is allowed to react with an organic metal reagent, sulfur (S) and then a compound of Formula IV. The resulting compound is then allowed to react with electrophilic compounds in the presence of a strong base. This step E suggests a very convenient method for carrying out the reaction in a single process .
Hereinafter, sub-steps of step E will be described. Protection of phenol group with Grignard reagent (Step E-I) Anhydrous solvents which can be used in this step include diethylether, tetrahydrofuran, hexane, heptane and a mixed solvent of two or more thereof. Among these solvents, preferred is diethylether, tetrahydrofuran or a mixed solvent of diethylether and tetrahydrofuran. A Grignard reagent used is methyl, ethyl, n-propyl, iso- propyl, n-butyl, sec-butyl magnesium chloride (R2MgCl) or alkyl magnesium bromide (R2MgBr) . Among these reagents, the most preferred is iso-propyl magnesium chloride (CH3JaCHMgCl).
The reaction temperature may vary depending on the kind of solvent used, but is generally -20 to 40 0C, and preferably 0 0C to room temperature (25 0C) . The reaction time may vary depending on the reaction temperature and the kind of solvent used, but is generally 10-60 minutes, and preferably 10-30 minutes. Halogen-to-lithium substitution and sulfur (S) introduction (Steps E-2 and E-3)
Organic metal reagents which can be used in halogen-to- lithium substitution reaction include n-butyllithium, sec- butyllithium and tert-butyllithium. Among these metal reagents, preferred is tert-butyllithium.
Sulfur (S) is preferably in the form of fine particle powder and is added for reaction after dissolution in an anhydrous tetrahydrofuran solvent or without dissolution. The reaction temperature may vary depending on the kind of solvent used, but is generally -78 to 25 °C, and preferably -75 0C for the halogen-to-metal substitution reaction, and room temperature (25 °C) starting from -75 °C for the sulfur introduction reaction. The reaction temperature is 10-30 minutes for the halogen-to-metal substitution reaction and 30-90 minutes for the sulfur introduction reaction.
Addition reaction of compound represented by Formula IV [Step E-4] 5-halogenmethyl-4-methyl-2- [4-
(trifluoromethyl) phenyl] thiazol of Formula IV used in this step is synthesized according to a known method (WO 2003/106442) . Examples of halogen in the formula IV compound include chlorine, bromine and iodine. Among these halogens, preferred is chlorine.
The reaction temperature may vary depending on the kind of solvent used, but is generally -78 °C to 25 0C, and preferably 0 0C to 10 0C. The reaction time is generally 10- 120 minutes, and preferably 10-60 minutes. Reactions with various electrophilic compounds (Step E-
Strong bases which can be used to treat the α-proton of thioether to prepare nucleophilic compounds include potassium tert-butoxide (t-BuO~K+) , lithium diisopropyl amide (LDA) , n- butyllithium, sec-butyllithium and tert-butyllithium. Among these bases, tert-butyllithium is most preferable.
The electrophilic compound that reacts with nucleophilic thioether compounds is a known compound which is commercially easily available or easily prepared according to the literature and contains highly reactive halogen, aldehyde or ketone. This compound is added for reaction after dissolution in anhydrous solvent or without dissolution.
The reaction temperature may vary depending on the kind of solvent used, but is generally -78 to 25 0C. Preferably, the alpha-hydrogen extraction with the strong base is carried out at -75 0C, and the electrophilic compounds are added at - 75 °C and allowed to react while elevating the temperature to room temperature (25 0C) . The reaction time varies depending on the reaction step, but is 10-30 minutes for the alpha- hydrogen extraction with the strong base, and 30-90 minutes for the reaction with the electrophilic compounds.
Step F: Preparation of compound represented by Formula IX To obtain a compound represented by Formula IX, a compound represented by Formula VII is preferably allowed to react with halogen acetic acid alkyl ester in the presence of a base. The halogen acetic acid alkyl ester is a known compound which is commercially easily available and in which the halogen is chlorine, bromine or iodine. The most preferred example of the halogen acetic acid alkyl ester is bromoacetic acid methyl ester or bromoacetic acid ethyl ester.
Solvents which can be used in this step include water- soluble solvents, such as N, N-dimethylformamide, N, N- dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethanol and methanol, or a mixture of any one thereof with 1- 10% water. Among these solvents, the most preferred is a mixture of acetone or dimethylsulfoxide with 1-5% water.
The base used is not specifically limited regardless of a strong base or weak base as long as it does not adversely affects the reaction, and examples thereof include alkali metal hydrides, such as sodium hydride and lithium hydride, alkaline earth metal hydride such as potassium hydride, alkali metal hydroxides, such as sodium hydroxide and potassium hydroxide, and alkali metal carbonates, such as lithium carbonate, potassium carbonate, potassium hydrogen carbonate and cesium carbonate. Among these bases, preferred is alkali metal carbonate, and more preferred is potassium carbonate .
The reaction temperature is not specifically limited as long as it is below the boiling point of a solvent used, but a reaction at a relatively high temperature is preferably avoided in order to suppress side reactions. The reaction temperature is generally 0-60 0C. The reaction temperature may vary depending on the reaction temperature, but is generally 30 minutes to 1 day, and preferably 30-90 minutes. Step G-I: Preparation of Compound represented by Formula X
A compound represented by Formula X is prepared by hydrolyzing the carboxylic ester of the compound of Formula IX with a water-soluble inorganic salt in alcohol solvent.
Solvents which can be used in this step include water- soluble alcohol solvents, such as methanol and ethanol.
Bases which can be used in this step include about 0.1-3 N aqueous solutions prepared using alkali metal hydroxides, such as lithium hydroxide, sodium hydroxide and potassium hydroxide, according to the form of carboxylic acid alkali salts. As an acid used to obtain the compound of Formula X in the form of carboxylic acid, acetic acid or 0.1-3ΛJ hydrochloric acid aqueous solution is preferably used. The reaction is preferably carried out at a relatively low temperature in order to inhibit side reactions, and is generally at 0 °C to room temperature. The reaction time may vary depending on the reaction temperature, but is generally 10 minutes to 3 hours, and preferably 30 minutes to 1 hour. Sep G-2: Preparation of compound represented by Formula X_
A compound represented by Formula X is prepared by substituting the allyl ester of the compound of Formula IX with a metal salt of 2-ethylhexanoate in an organic solvent in the presence of a metal catalyst.
The solvent used in this step is an anhydrous organic solvents, such as chloroform, dichloromethane or ethyl acetate. ^
As the metal catalyst, palladium tetrakistriphenylphosphin is preferably used in an amount of 0.01-0.1 equivalent.
The reaction is preferably carried out at a relatively low temperature in order to inhibit side reactions, and is generally conducted at 0 °C to room temperature. The reaction time may vary depending on the reaction temperature, but is generally 10 minutes to 3 hours, and preferably 30 minutes to 1 hour. This salt compound is separated with high purity by centrifugation. The obtained metal salt-type compound of Formula X is easier to separate than the salt-type compound prepared using the step G-I (hydrolysis step) .
The Y-shaped thiazole compounds of Formula X thus obtained are important substances as ligands for PPARδ. Also, these compounds have chiral carbon, and so stereoisomers thereof exist. Among the compounds of Formula X, R-form or S-form isomers are confirmed to be effective compared to racemates, and the scope of the present invention encompasses the compounds of Formula X, and their stereoisomers, solvates and salts.
Advantageous Effects
As described above, the novel thiazole derivative compounds according to the present invention have the characteristics of PPARδ-activating ligands and show a high possibility to be used as agents for treating cardiovascular disease, lowering cholesterol levels and treating diabetes and obesity. Also, the inventive preparation method is useful for the preparation of the thiazole derivative compounds .
Best Mode Mode for Invention
Examples
Hereinafter, the method according to the present invention will be described in further detail by examples. It will however be obvious to a person skilled in the art that the present invention is not limited to or by these examples.
Example 1: Preparation of 4-iodo-2-methyl-phenoxy-tert- butyldimethyl silane (III) [Step A] 3.O g (12.8 mmol) of 4-iodo-2-methylphenol and 1.74 g
(25.6 mmol, 2.0 equivalents) of imidazole were completely dissolved in 45 ml of dimethylformamide. To the solution,
2.12 g (14.1 mmol, 1.1 equivalents) of tert- butyldimethylsilyl chloride was slowly added, and the mixture was stirred at room temperature for 4 hours. After completion of the reaction, the reaction product was extracted with aqueous ammonium chloride solution and ethyl acetate, and the organic layer was dried over magnesium sulfate. The residue was purified with a silica gel column, and the solvent was removed by distillation under reduced pressure, thus obtaining 4.4 g (98% yield) of the title compound. 1H NMR (300 MHz, CDCl3) 67.47 (d, IH, J = 0.6 Hz) , 7.35 (dd, IH, J = 8.4, 2.3 Hz) , 6.54 (d, IH, J = 8.4 Hz) , 2.18 (s, 3H) , 1.03 (s, 9H) , 0.22 (s, 6H) .
13C NMR (75.5 MHz, CDCl3) 5154.3, 139.9, 135.9, 132.3, 121.1, 83.9, 26.2, 18.7, 17.0, -3.8.
Example 2: Preparation of 4-bromo-phenoxy- tert- butyldimethyl silane (III) [Step A]
500 mg (2.90 mmol) of 4-bromophenol and 409 mg (6.0 mmol, 2.00 equivalents) of imidazole were completely dissolved in dimethylformamide . To the solution, 436 mg
(2.90 mmol, 1.0 equivalent) of tert-butyldimethylsilyl chloride was slowly added, and the mixture was stirred at room temperature for 4 hours. After completion of the reaction, the reaction product was extracted with aqueous ammonium chloride solution and ethyl acetate, and the organic layer was dried over magnesium sulfate. The residue was purified with a silica gel column, and the solvent was removed by distillation under reduced pressure, thus obtaining 811 mg (97% yield) of the title compound. 1H NMR (300 MHz, CDCl3) 57.32 (d, 2H, J = 8.8 Hz), 6.72 (d, 2H, J= 10.0 Hz), 0.98 (s, 9H), 0.18 (s, 6H)
13C NMR (75.5 MHz, CDCl3) 5155.3, 132.7, 122.3, 114.0, 26.0, 18.6, -4.1
Example 3j Preparation of 5- [4- ( tert- butyldimethylsilyloxy) -3-methyl-phenylsulfanylmethyl] -4- methyl-2- [ (4-trifluoromethyl) phenyl] -thiazole (V) [Step B]
In a nitrogen atmosphere, 1.5 g (4.32 mmol) of 4-iodo-2- methyl-phenoxy- tert-butyldimethyl silane prepared in Example 1 was dissolved in 120 ml of anhydrous tetrahydrofuran and cooled to -78 0C. To the solution, 2.54 ml (1.0 equivalent) of tert-butyllithium (1.7 M-hexane solution) was slowly added. The mixture was stirred for 10 minutes, to which 138 mg (4.32 mmol, 1.0 equivalent) of solid phase sulfur was then added at a time at the same temperature. The mixture was allowed to react for 40 minutes until it reached a temperature of 15 °C, to which 1.26 g (4.32 mmol, 1.0 equivalent) of 5- chloromethyl-4-methyl-2- [ (4-trifluoromethyl) phenyl] -thiazol of Formula III dissolved in 10 ml of anhydrous THF was then slowly added. After reaction for an additional time of about one hour, the reaction was terminated with aqueous ammonium chloride solution, and the reaction product was extracted with ethyl acetate and aqueous salt solution, and the organic layer was dried over magnesium sulfate. After filtration, the solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography, thus obtaining 1.85 g (84 % yield) of the title compound.
1H NMR (300 MHz, CDCl3) 57.97 (d, 2H, J = 8.0 Hz), 7.65 (d, 2H, J = 8.2 Hz), 7.17 (d, IH, J = 1.8 Hz), 7.07 (dd, IH, J = 8.2, 2.3 Hz), 6.67 (d, IH, J= 8.3Hz), 4.10 (s, 2H), 2.20 (s, 3H), 2.15 (s, 3H), 1.00 (s, 9H), 0.20 (s, 6H).
13C NMR (75.5 MHz, CDCl3) 5163.4, 154.9, 151.8, 136.8, 132.6, 130.4, 129.6 (q, J = 32 Hz), 126.8, 126.2 (m) , 125.2, 119.6, 33.0, 26.1, 18.7, 17.1, 15.2, -3.9.
Example 4: Preparation of 5- [1- [3-methyl-4- ( tert- butyldimethylsilyloxy) phenylthio] -3-phenylpropyl] -2- [4- (trifluoromethyl) phenyl] -4-methylthiazole (VI) [Step C] In a nitrogen atmosphere, 510 mg (1.0 mmol) of 5- [4- ( tert-butyldimethylsilanyloxy) -3-methyl- phenylsulfanylmethyl] -4-methyl-2- [ (4-trifluoromethyl) phenyl] - thiazole prepared in Example 3 was dissolved in 20 ml of anhydrous tetrahydrofuran. The reaction solution was sufficiently cooled to -78 0C, to which 1.2 ml (2.0 equivalents) of tert-butyllithium (1.7 M-heptane solution) was then slowly added. While the reaction solution maintained a deep blue color, 137 μl (1.0 mmol) of (2- bromoethyl) benzene was added thereto, and the reaction temperature was slowly elevated to room temperature. After reduction for an additional time of about 30 minutes, the reaction was terminated with aqueous ammonium chloride solution, and the reaction product was extracted wit ethyl acetate and aqueous salt solution, and the organic layer was dried over magnesium sulfate. After filtration, the solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography, thus obtaining 388 mg (63 % yield) of the title compound. 1H NMR (300 MHz, CDCl3) 57.99 (d, 2H, J = 8.5 Hz), 7.67 (d, 2H, J = 8.2 Hz), 7.19 (m, 5H), 7.04 (d, IH, J = 2.0 Hz), 6.96 (dd, IH, J = 8.3, 2.4 Hz), 6.59 (d, IH, J = 8.3 Hz), 4.19 (dd, IH, J = 8.9, 6.0 Hz), 2.74 (m, 2H), 2.37 (m, IH), 2.37 (m, IH), 2.19 (m, IH), 2.08 (s, 3H), 1.96 (s, 3H), 0.98 (s, 9H) , 0.17 (s, 6H) . Examples 5 to 34
Compounds shown in Table 1 below were prepared in the same manner as described in Example 4, and the NMR data of the prepared compounds are shown in Table 2 below. [Table 1]
Example32 -CH3 -TBDMS H
Example 33 -CHa -TBDMS
Example34 -CH3 -TBDMS H
[Table 2]
Example 35: Preparation of 4-[l-[2-[4-
(trif luoromethyl) phenyl] -4-methylthiazol-5-yl] -6- phenylhexylthio] -2-methylphenol (VII) [Step D] o
394 mg (0.6 mmol) of 5- [1- [ 3-methyl-4- ( tert- butyldimethylsilyloxy) phenylthio] -β-phenylhexyl] -2- [4- (trifluoromethyl) phenyl] -4-methylthiazol was completely dissolved in 10 ml of tetrahydrofuran. To the solution, 1.5 ml (2.5 equivalents) of tetrabutylammonium fluoride (TBAF) (1 M-tetrahydrofuran solution) was slowly added at room temperature. After reaction for 30 minutes, the reaction product was extracted with aqueous ammonium chloride solution and ethyl acetate, and the organic layer was dried over magnesium sulfate. After filtration, the solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography, thus obtaining 306 mg (94 % yield) of the title compound.
1H NMR (300 MHz, CDCl3) 57.98 (d, 2H, J = 8.0 Hz), 7.66 (d, 2H, J = 8.2 Hz), 7.19 (m, 5H), 7.09 (d, IH, J = 1.5 Hz), 6.93 (dd, IH, J = 7.8, 1.9 Hz), 6.57 (d, IH, J = 8.2 Hz), 4.20 (dd, IH, J = 9.1, 5.9 Hz), 2.58 (t, 2H, J = 7.5 Hz), 2.18 (s, 3H), 2.04 (m, IH), 1.97 (s, 3H), 1.85 (m, IH), 1.60 (m, 2H) , 1.39 (m, 4H) . Examples 36 to 38
Compounds shown in Table 3 below were prepared according to the method of Example 35, and the NMR data of the prepared compounds are shown in Table 4 below. [Table 3]
[Table 4]
Example 39: Preparation of 4- [2- (2-chloro-6- fluorophenyl) -1- [2- [4- (trifluororαethyl) phenyl] -A- methylthiazol-5-yl] ethylthio] -2-methylphenol (VII) from compound of Formula II [Step E] In a nitrogen atmosphere, 585 mg (2.5 mmol) of 4-iodo- 2-methylphenol was dissolved in 35 ml of anhydrous tetrahydrofuran and maintained at a temperature of 0 0C. To the solution, 1.3 ml (1.0 equivalent) of isopropyl magnesium chloride (2 M-ether solution) was slowly added and the mixture was allowed to react for 10 minutes. After the reaction solution was sufficiently cooled to -78 0C, 3.0 ml (2.0 equivalents) of tert-butyllithium (1.7 M-heptane solution) was added dropwise thereto, and the mixture was allowed to react for 20 minutes. To the reaction product, 80 mg (2.5 mmol, 1.0 equivalent) of solid phase sulfur was added at a time, and the reaction mixture was allowed to react until it reached a temperature of 15 °C. After 40 minutes, 730 mg (2.5 mmol, 1.0 equivalent) of 5-chloromethyl-4-methyl- 2- [ (4-trifluoromethyl) phenyl] -thiazole of Formula IV dissolved in 3 ml of anhydrous THF was added to the reaction product at the same temperature. After reaction for an additional time of about 20 minutes, the reaction material was sufficiently cooled to -78 °C. Then, 3.0 ml (2.0 equivalents) of tert-butyllithium (1.7 M-heptane solution) was added dropwise to the reaction solution, and when the reaction solution turned a blue color, 345 μl (2.5 mmol) of 2-chloro-6-fluorobenzyl bromide was added thereto at the same temperature. The mixture was allowed to react while elevating the temperature slowly to room temperature. After 20 minutes, 30 ml of aqueous ammonium chloride solution was added to terminate the reaction. The organic layer was separated and dried over magnesium sulfate. After filtration, the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography using hexane/ethyl acetate (v/v = 3/1), thus obtaining 1.12 g (83% yield) of the title compound.
1H NMR (300 MHz, CDCl3) 57.97 (d, 2H, J = 8.1 Hz), 7.64 (d, 2H, J = 8.2 Hz), 7.14 (m, 3H), 6.98 (dd, IH, J = 8.2, 2.1 Hz), 6.90 (m, IH), 6.55 (d, IH, J = 8.3 Hz), 4.74 (dd, IH, J = 8.7, 6.8 Hz), 3.40 (m, 2H), 2.18 (s, 3H), 1.85 (s, 3H). Examples 40 to 41
Compounds shown in Table 5 below were prepared according to the method of Example 39, and the NMR data of the prepared compounds are shown in Table 6 below. [Table 5]
[Table 6]
Example 42: Preparation of 2-[4- [l-[2- 14-
(trif luoromethyl ) phenyl] -4-methylthiazol-5-yl] -A- phenylbutylthio] -2-methylphenoxy] acetic acid ethyl ester Of
Formula IX [Step F]
At room temperature, 205 mg (0.4 rtiraol) of 2-methyl-4- [1- [4-methyl-2- (4-trifluoromethyl-phenyl) thiazol-5-yl] -4- phenyl-butylsulfanyl] phenol was well mixed with 10 ml of acetone containing 5% water and 127 mg (0.92 mmol, 2.3 equivalents) of potassium carbonate. To the solution, 67 μl (0.6 mmol, 1.5 equivalents) of bromoacetic acid ethyl ester was added and the mixture was strongly stirred for 4 hours. After completion of the reaction, the reaction product was extracted with aqueous salt solution and ethyl acetate and the organic layer was dried over magnesium sulfate. After filtration, the solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using hexane/ethyl acetate (v/v = 5:1), thus obtaining 230 mg (96% yield) of the title compound.
1H NMR (300 MHz, CDCl3) 57.98 (d, 2H, J = 8.2 Hz), 7.66 (d, 2H, J= 8.5 Hz), 7.19 (m, 6H), 7.01 (dd, IH, J = 8.4, 2.2 Hz), 6.52 (d, IH, J = 8.4), 4.59 (s, 2H), 4.23 (m, 3H), 2.63 (t, 2H, J= 8.4 Hz), 2.19 (s, 3H), 2.08 (m, IH), 2.02 (s, 3H), 1.90 (m, IH), 1.73 (m, 2H), 1.27 (t, 3H, J = 7.2 Hz).
13C NMR (75.5 MHz, CDCl3) 5168.9, 163.3, 156.9, 151.2, 141.8, 137.8, 137.1, 137.0, 133.8, 131.6 (q, J = 33 Hz), 128.6, 128.6, 128.3, 126.5, 126.2, 126.0 (q, J= 4 Hz), 124.6, 111.5, 65.7, 61.6, 47.5, 37.3, 35.6, 29.6, 16.3, 15.2, 14.3.
Example 43: Preparation of 2- [4- [2- (2-chloro-6- fluorophenyl) -1- [2- [4- (trifluoromethyl) phenyl] -4- methylthiazol-5-yl] ethylthio] -2-methylphenoxy] acetic acid allyl ester of Formula IX [Step F]
At room temperature, 200 mg (0.37 mmol) of 4- (2- (2- chloro-β-fluorophenyl) -1- (2- (4- (trifluoromethyl) phenyl) -A- methylthiazol-5-yl) ethylthio) -2-methylphenol prepared in Example 37 was well mixed with 10 ml of acetone containing 5% water and 102 mg (0.74 mmol, 2 equivalents) of potassium carbonate. To the solution, 73 mg (0.40 mmol, 1.1 equivalents) of bromoacetic acid allyl ester was added and the mixture was strongly stirred for 4 hours. After completion of the reaction, the reaction product was extracted with aqueous salt solution and ethyl acetate, and the organic layer was dried over magnesium sulfate. After filtration, the solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using a mixed solvent of hexane/ethyl acetate (v/v = 5:1), thus obtaining 221 mg (94% yield) of the title compound.
1H NMR (300 MHz, CDCl3) δ 7.60-7.76 (m, 3H), 7.11-7.17 (m, 4H), 6.90 (m, IH), 6.55 (d, IH, J= 8.4 Hz), 5.89 (m, IH), 5.34 (m, IH), 5.24 (m, IH), 4.79 (dd, IH, J = 8.8, 6.6 Hz), 4.68 (m, 2H), 4.59 (s, 2H), 3.38 (m, 2H), 2.20 (s, 3H), 1.90 (s, 3H) .
Examples 44 to 67
Compounds shown in Table 7 below were prepared according to the method of Example 42, and the NMR data of the prepared compounds are shown in Table 8 below. [Table 7]
[Table 8]
Example 68 : Preparation of 2-[4-[l-[2-[4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -3- phenylpropylthio] -2-methylphenoxy] acetic acid of Formula X [Step G]
178 mg (0.3 mmol) of 2- [4- [1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5-yl] -3- phenylpropylthio] -2-methylphenoxy] acetic acid ethyl ester was well mixed with 15 ml of ethanol. To the solution, 1.0 ml of 3 N-sodium hydroxide aqueous solution was added and the mixture was stirred at room temperature for 20 minutes. After completion of the reaction, the reaction product was adjusted to pH 2.0 with 2 N-HCl. 80% of the ethanol solvent was removed by distillation under reduced pressure, and the remaining material was extracted with aqueous salt solution and ethyl acetate. Then, the solvent was removed by distillation under reduced pressure, and the residue was purified by LH-20 column chromatography, thus obtaining 166 mg (99% yield) of the title compound.
1H NMR (300 MHz, CDCl3) 57.98 (d, 2H, J = 8.1 Hz), 7.68 (d, 2H, J = 8.3 Hz), 7.26 (m, 3H), 7.12 (m, 3H), 6.99 (dd, IH, J = 8.4, 2.2 Hz), 6.55 (d, IH, J = 8.5 Hz), 4.64 (s, IH), 4.20 (dd, IH, J = 8.9, 6.1 Hz), 3.85 (s, 2H), 2.73 (m, 2H), 2.38 (m, IH), 2.20 (m, IH), 2.17 (s, 3H), 1.89 (s, 3H).
Example 69: Preparation of potassium 2- [4- [2- (2-chloro- 6-fluorophenyl) -1- [2- [4- (trifluoromethyl) phenyl] -4- methylthiazol-5-yl] ethylthio] -2-methylphenoxy] acetate of Formula X [Step G]
200 mg (0.31 mmol) of 2- [4- [2- (2-chloro-6-fluorophenyl) - 1- [2- [4- (trifluoromethyl) phenyl] -4-methylthiazol-5- yl] ethylthio] -2-methylphenoxy] acetic acid allyl ester and 18 mg (0.015 mmol, 0.05 equivalents) of palladium tetrakistriphenylphosphine were dissolved in 10 ml of anhydrous dichloromethane and stirred at room temperature. To the reaction solution, 56 mg (0.31 mmol, 1.0 equivalent) of potassium 2-ethylhexanoate dissolved in 1 ml of anhydrous dichloromethane was slowly added. The mixture was stirred at room temperature for 1 hour, and the solvent was then removed by centrifugation. The remaining solid was washed with 10 ml of dichloromethane and 10 ml of n-hexane and dried, thus obtaining 179 mg (91% yield) of the title compound. 1H NMR (300 MHz, D2O) δ 7.96 (d, 2H, J"= 8.1 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.17 (m, 5H) 6.91 (m, IH), 6.56 (d, IH, J = 8.5 Hz), 4.79 (dd, IH, J = 8.5, 6.9 Hz), 4.66 (s, 2H), 3.39 (m, 2H), 2.18 (s, 3H), 1.87 (s, 3H). Examples 70 to 97 Compounds shown in Table 9 below were prepared according to the method of Example 68, and the NMR data of the prepared compounds are shown in Table 10 below. Herein, the NMR spectra of compounds wherein Rδb is an alkali metal (sodium or potassium) were identical to those of compounds wherein R6b is hydrogen.
[Table 9]
[Table 10]
1H NMR (300 MHz, CDCI3)
7.98 (d, 2H, J = 8.1 Hz), 7.68 (d, 2H, J = 8.3 Hz), 7.26 (m, 3H), 7.12| (m, 3H), 6.99 (dd, 1H, J= 8.4, 2.2 Hz), 6.55 (d, 1H, J= 8.5 Hz), 4.64J
Example68 (s, 1H), 4.20 (dd, 1H, J = 8.9, 6.1 Hz), 3.85 (s, 2H), 2.73 (m, 2H), 2.38 (m, 1H), 2.20 (m, 1H), 2.17 (s, 3H), 1.89 (s, 3H)
7.96 (d, 2H, J= 8.1 Hz), 7.66 (d, 2H, J= 8.3 Hz), 7.17 (m. 5H) 6.91 Example69 (m, 1H), 6.56 (d, 1H, J= 8.5 Hz), 4.79 (dd, 1H, J= 8.5, 6.9 Hz), 4.66 (s, 2H), 3.39 (m, 2H), 2.18 (s, 3H), 1.87 (s, 3H)
7.94 (d, 2H, J = 8.2 Hz), 7.66 (d, 2H, J = 8.2 Hz), 7.18 (m, 6H), 6.97
(dd, 1H, J= 8.3, 1.5 Hz), 6.52 (d, 1H, J= 8.4 Hz), 5.80 (s, 1H), 4.60
Example 70
(s, 2H), 4.23 (dd, 1H, J= 8.3, 6.1 Hz), 2.64 (t, 2H, J= 7.5 Hz), 2.16 (s, 3H), 2.07 (m, 1H), 1.93 (s, 3H), 1.88 (m, 1H), 1.76 (m, 2H)
7.96 (d, 2H, J = 8.2 Hz), 7.66 (d, 2H, J = 8.2 Hz), 7.20 (m, 6H), 6.99 (dd, 1H, J= 8.3. 1.5 Hz), 6.53 (d, 1H. J= 8.4 Hz), 5.39 (s, 1H), 4.61
Example 71 (s, 2H), 4.23 (dd, 1H, J = 8.8, 6.1 Hz), 2.59 (m. 2H), 2.17 (s, 3H), 1.88 (m, 1H), 1.94 (s, 3H), 1.91 (m, 1H), 1.65 (m, 2H), 1.46 (m.2H)
7.96 (d, 2H, J = 8.4 Hz), 7.66 (d, 2H, J = 8.5 Hz), 7.63 (s, 1H), 7.20 (m, 6H), 6.98 (dd, 1H, J= 8.3, 2.2 Hz), 6.54 (d, 1H, J= 8.5 Hz), 4.59
Example72 (s, 2H), 4.22 (dd, 1H, J= 9.0, 6.0 Hz), 2.58 (t, 2H, J= 7.6 Hz), 2.17 (s, 3H), 2.03 (m, 1H), 1.93 (s, 3H), 1.89 (m, 1H). 1.61 (m, 2H), 1.42 (m, 4H)
7.96 (d, 2H, J = 8.1 Hz), 7.71 (s, 1H), 7.66 (d, 2H, J = 8.3 Hz), 7.20
(m, 6H), 6.98 (dd, 1H, J= 8.4, 2.2 Hz), 6.54 (d, 1H, J= 8.5 Hz), 4.6
Example73 (s, 2H), 4.23 (dd, 1H, J= 9.0, 6.0 Hz), 2.58 (t, 2H, J= 7.6 Hz), 2.17
(s, 3H), 2.03 (m, 1H), 1.95 (s, 3H), 1.89 (m, 1H), 1.61 (m, 2H), 1.28 (m, 8H)
7.96 (d, 2H, J =8.1 Hz), 7.66 (d, 2H, J= 8.3 Hz), 7.18 (m, 6H), 6.99 (dd, 1H, J= 8.3, 1.8 Hz), 6.54 (d, 1H, J= 8.5 Hz), 4.91 (s, 1H), 4.6 Example 74 (s, 2H), 4.24 (dd, 1H, J = 9.0, 5.9 Hz), 2.58 (t, 2H, J= 7.6 Hz), 2.17 (s, 3H), 2.03 (m, 1H), 1.95 (s, 3H), 1.85 (m, 1H), 1.59 (m, 2H), 1.28 (m, 14H)
Test Example 1 : Activity and cytotoxicity tests The compounds prepared in Examples were tested for PPARδ activity by a transfection assay. In addition, the compounds were tested for selectivity for PPARα and PPARγ, the subtypes of PPARs, and also tested for toxicity by a MTT assay.
Transfection assay A transfection assay was performed using CV-I cells. The culture of the cells was performed using a DMEM medium (10% FBS, DBS (delipidated) and 1% penicillin/streptomycin) on a 96-well plate in a 5% carbon dioxide-containing incubator at 37 °C. The test was performed in four steps consisting of cell inoculation, transfection, treatment of the compounds, and analysis of results. Specifically, CV-I cells were inoculated onto a 96-well plate at a concentration of 5,000 cells/well, and after 24 hours, the cells were transfected. In the cell transfection, full-length PPARs plasmid DNA, reporter DNA that has luciferase activity and thus allows the identification of PPARs, and β-galactosidase DNA that provides the information of transfection efficiency, were used as transfection reagents. Each of the compounds developed in the present invention was dissolved in dimethylsulfoxide (DMSO) and transfected into the cells at various concentrations using media. The cells were cultured in an incubator for 24 and then lysed with lysis buffer. The lysed cells were measured for luciferase and β-galactosidase activities using a luminometer and a microplate reader. The measured luciferase values were normalized with the β- galactosidase values and graphed. From the graph, EC50 values were determined.
The EC50 values of the compounds prepared in Examples 47-97 according to the present invention were mostly less than 50 nM, and the compounds showed at least 10, 000-fold selectivity for PPARα and PPARγ. MTT assay The compounds of Examples 47-97 according to the present invention were tested for cytotoxicity using a MTT assay. MTT is a water-soluble yellow substance, but if it is introduced into living cells, it will be degenerated into a water-insoluble purple crystal due to dehydrogenase contained in mitochondria. If this substance is dissolved in dimethylsulfoxide and then measured for absorbance at 550 nm, cytotoxicity can be assayed. The test method is as follows.
CV-I cells were first inoculated onto a 96-well plate at a concentration of 5,000 cells/well. The inoculated cells were cultured in a 5% carbon dioxide-containing humidified incubator at 37 0C for 24 hours, and then treated with the inventive compounds at various concentrations. After 24 hours of culture, a MTT reagent was added to the cultured cells. After 15 minutes of culture, the resulting purple crystal was dissolved in dimethylsulfoxide and then measured for absorbance using a microplate reader. From the measured absorbance, cytotoxicity was assayed.
The test results showed that most of the inventive compounds had no cytotoxicity even at a concentration of 90 μM.
Industrial Applicability
The present invention provides novel thiazole derivatives as peroxisome proliferator-activated receptor δ
(PPARδ) -activating ligands, which can be used for treatment of obesity, hyperlipidemia, arteriosclerosis and diabetes, as well as their intermediates and preparation methods thereof.
The present invention is useful to provide novel thiazole derivative compounds as PPARδ-activating ligands.

Claims

What Is Claimed Is:
1. Thiazole derivatives of Formula I as racemates or optical isomers: [Formula I]
wherein A is hydrogen, R2 or
Ri is a hydrogen atom, a C1-4 alkyl group, a C1-4 alkyloxy group, a Ci-4 alkylthioxy group, a Ci_4 alkylamine group, a fluorine atom or a chlorine atom;
M is an integer from 0 to 4;
R2 is a phenol-protecting group selected from among C1-4 lower alkyl groups, allyl groups, alkylsilyl groups, alkylarylsilyl groups and a tetrahydropyranyl group;
R3 groups are different from each other and denote a hydrogen atom, a halogen atom, or a Ci_4 alkyl or alkoxy group substituted or unsubstituted with halogen;
N is an integer from 0 to 5;
R5 is a hydrogen atom, a hydroxyl group or a Ci_4 alkyl group; Rε is a carboxylic acid protecting group having C1-4 alkyl, an allyl group, a hydrogen atom or an alkali metal; Rn is an arylaminoalkyl group or an alkylaminoalkyl group; Ri2 is a halogen atom, a cyano group, or a Ci-4 alkyl or alkoxy group substituted with unsubstituted with halogen; Ri3 is a hydrogen atom, a halogen atom, a cyano group, a Ci-4 alkyl or alkoxy group substituted with unsubstituted with halogen; o, p and q are each independently an integer from 1 to 5; and r is an integer from 1 to 9.
2. The thiazole derivatives of Claim 1, which are represented by Formula VI: [Formula VI]
wherein Ri to R5, m and n have the same meanings as defined in Formula I .
3. The thiazole derivatives of Claim 1, which are represented by Formula VII: [Formula VII]
wherein Ri, R3 to R5, m and n have the same meanings as defined in Formula I.
4. The thiazole derivatives of Claim 1, which are represented by Formula IX: [Formula IX] wherein Ri, R3 to R5, m and n have the same meanings as defined in Formula I, and R6a is a carboxylic acid protecting group having C1^4 alkyl or an allyl group.
5. The thiazole derivatives of Claim 1, which are represented by Formula X: [Formula X]
wherein Ri, R3 to R5, m and n have the same meanings as defined in Formula I, and Rβb is a hydrogen atom or an alkali metal .
6. A method for preparing thiazole derivatives, comprising the steps of: a) reacting a 4-halogen phenol compound of Formula II with a phenol-protecting alkylsilyl group in the presence of a base to prepare a compound of Formula III; b) subjecting the compound of Formula III to halogen-to- lithium substitution, and then to reaction with sulfur and a compound of Formula IV so as to prepare a compound of Formula V; and c) reacting the compound of Formula V with a strong base and an electrophilic compound so as to prepare a compound of Formula VI : [Formula II]
[Formula III]
\ Formula IV]
[ Formula V]
[ Formula VI ]
wherein Xi denotes a bromine atom or an iodine atom, X2 denotes a chlorine atom, a bromine atom, an iodine atom, or a leaving group having high reactivity in nucleophilic substitution reaction, and the remainder has the same meanings as defined in Formula I .
7. The method of Claim 6, which further comprises the step of: d) removing the phenol-protecting silyl group of a compound of Formula VI so as to prepare a compound of Formula VII:
[ Formula VI ]
[ Formula VI I ]
wherein Ri to R5, m and n have the same meanings as defined in Formula I .
8. A method for preparing thiazole derivatives, comprising the steps of: reacting a 4-halogen phenol compound of Formula II with a Grignard reagent, subjecting the reaction product to halogen-to-lithium substitution and then reacting the reaction product with sulfur and the compound of Formula IV so as to form a thioether compound; and reacting the thioether compound with a strong base without separation and then with an electrophilic compound so as to prepare a compound of Formula VII: [Formula II]
[ Formula IV ]
[ Formula VI I ]
wherein Xi denotes a bromine atom or an iodine atom, X2 denotes a chlorine atom, a bromine atom, an iodine atom, or a leaving group having high reactivity in electrophilic substitution reaction, and Ri, R3 to R5, m and n have the same meanings as defined in Formula I .
9. The method of Claim 7 or 8, which further comprises the step of: e) reacting the compound of Formula VII with an alkyl halogen acetate of Formula VIII in the presence of an inorganic salt so as to prepare a compound of Formula IX: [Formula VII]
[ Formula VI I I ]
O X4^-^OR6 [ Formula IX] wherein Ri, R3 to R5, m and n have the same meanings as defined in Formula I, and Rβa is a carboxylic acid protecting group having C1-4 alkyl or an allyl group, and X4 is a chlorine atom, a bromine atom or an iodine atom.
10. The method of Claim 9, which further comprises the step of: subjecting the compound of Formula IX to carboxylic acid ester hydrolysis with a water-soluble inorganic salt in an alcohol solution so as to prepare a compound of Formula X: [Formula IX]
[Formula X]
wherein Ri, R3 to R5, m and n have the same meanings as defined in Formula I, R6a is a carboxylic acid protecting group having C1-4 or an allyl group, and Rδb is a hydrogen atom or an alkali metal.
11. The method of Claim 9, which further comprises the step of: subjecting the compound of Formula IX to allyl ester-to- salt substitution using a metal salt in an organic solvent in the presence of a palladium tetrakistriphenylphosphine catalyst so as to prepare a compound of Formula X:
wherein Ri, R3 to R5, m and n have the same meanings as defined in Formula I, and M is an alkali metal.
12. An agent for treating diabetes, comprising as an active ingredient a thiazole derivative represented by Formula I .
13. An agent for preventing and treating obesity, comprising as an active ingredient a thiazole derivative represented by Formula I .
14. An agent for preventing and treating arteriosclerosis, comprising as an active ingredient a thiazole derivative represented by Formula I.
15. An agent for preventing and treating hyperlipidemia, comprising as an active ingredient a thiazole derivative represented by Formula I . JQ
16. Health food supplement, health beverage, food additive, functional cosmetic and animal feed compositions comprising as an active ingredient a thiazole derivative represented by Formula I .
17. A composition for activating a peroxisome proliferator-activated receptor δ (PPARδ), comprising as an active ingredient a thiazole derivative represented by Formula I.
EP06716113A 2005-02-25 2006-02-24 Thiazole derivatives as ppar delta ligands and their manufacturing process Withdrawn EP1856072A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20050015663 2005-02-25
KR1020060018360A KR100797798B1 (en) 2005-02-25 2006-02-24 Thiazole derivatives as ppar? ligands and their manufacturing process
PCT/KR2006/000663 WO2006091047A1 (en) 2005-02-25 2006-02-24 Thiazole derivatives as ppar delta ligands and their manufacturing process

Publications (2)

Publication Number Publication Date
EP1856072A1 true EP1856072A1 (en) 2007-11-21
EP1856072A4 EP1856072A4 (en) 2009-10-21

Family

ID=36927652

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06716113A Withdrawn EP1856072A4 (en) 2005-02-25 2006-02-24 Thiazole derivatives as ppar delta ligands and their manufacturing process

Country Status (3)

Country Link
EP (1) EP1856072A4 (en)
CA (1) CA2599281C (en)
WO (1) WO2006091047A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102584685A (en) 2006-12-02 2012-07-18 财团法人首尔大学校产学协力财团 Aryl compounds as PPAR ligands and their use
WO2008084962A1 (en) * 2007-01-08 2008-07-17 Seoul National University Industry Foundation THIAZOLE COMPOUND (AS PPARδ) LIGAND AND PHARMACEUTICAL, COSMETIC AND HEALTH FOOD COMPRISED THEREOF
US20120316346A1 (en) * 2010-02-25 2012-12-13 Snu R & Db Foundation Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds
BR112013004882A2 (en) 2010-08-31 2016-05-03 Snu R&Db Foundation use of fetal reprogramming of ppar delta agonist

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062774A1 (en) * 2000-12-20 2002-08-15 Glaxo Group Limited Thiazole derivatives for treating ppar related disorders
WO2003072100A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2003106442A1 (en) * 2002-05-04 2003-12-24 Heonjoong Kang Process for preparing thiazole derivative and the intermediate compounds for preparing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL345247A1 (en) * 1998-07-01 2001-12-03 Takeda Chemical Industries Ltd Retinoid-associated receptor regulators
CA2367356A1 (en) * 1999-04-20 2000-10-26 Per Sauerberg New compounds, their preparation and use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062774A1 (en) * 2000-12-20 2002-08-15 Glaxo Group Limited Thiazole derivatives for treating ppar related disorders
WO2003072100A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2003106442A1 (en) * 2002-05-04 2003-12-24 Heonjoong Kang Process for preparing thiazole derivative and the intermediate compounds for preparing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006091047A1 *

Also Published As

Publication number Publication date
EP1856072A4 (en) 2009-10-21
CA2599281A1 (en) 2006-08-31
WO2006091047A1 (en) 2006-08-31
CA2599281C (en) 2012-01-17

Similar Documents

Publication Publication Date Title
RU2444514C2 (en) Aryl compounds as ppar ligands and their application
JP3490704B2 (en) Thiazole and oxazole derivatives and their pharmaceutical use
JP5367584B2 (en) Peroxisome proliferator-activated receptor δ ligand thiazole compound and pharmaceutical, cosmetic and health food composition containing the same
HRP20040810A2 (en) Thiazole and oxazole derivatives that modulate ppar activity
KR20040091693A (en) Thiazole and oxazole derivatives which modulate ppar activity
EP1349843A1 (en) Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
JP5191744B2 (en) Thiazole derivative of peroxisome proliferator activated receptor delta ligand and method for producing the same
CA2599281C (en) Thiazole derivatives as ppar delta ligands and their manufacturing process
JP2013525267A (en) Selenazole derivative of peroxisome proliferator activated receptor ligand, method for producing the same and use of the compound
CZ20033252A3 (en) Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor
AU2010221808B2 (en) Organoselenium containing compounds and their use
KR100753860B1 (en) Organoselenium containing compounds and their use
KR101141556B1 (en) Selenazole derivatives as ppar ligands, their manufacturing process and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION

A4 Supplementary search report drawn up and despatched

Effective date: 20090921

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20090915BHEP

Ipc: A61P 3/06 20060101ALI20090915BHEP

Ipc: A61K 31/426 20060101ALI20090915BHEP

Ipc: C07D 277/26 20060101AFI20060904BHEP

17Q First examination report despatched

Effective date: 20091215

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140410

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HWANG, HOOSANG

Inventor name: HAM, JUNGYEOB

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140821